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Abstract 
 
Aptamers are artificial nucleic acid ligands that can be engineered to bind to with high 
specificity to a macromolecule. Their binding specificity and small size allow for a range of 
therapeutic applications.  One avenue of research is to develop aptamers with specific and 
strong affinity to the HIV-1 envelope glycoprotein gp120. Aptamers could act as novel HIV-
1 entry inhibitor drugs or as targeted drug delivery systems to HIV-1 infected cells. Prior to 
any downstream applications, novel gp120 aptamers need to be biophysically characterised 
with regards to their target binding characteristics. Eight aptamers (B11, B19, B84, B65, B5, 
P10, P2 and T58) that have been previously isolated against gp120 and effectively block 
HIV-1 entry into target cells were used in this study. Secondary structures of selected anti-
gp120 aptamers were computationally determined and analysed. Between one and five 
structures were predicted for each aptamer. The relative stability of the aptamers was 
analysed and B11 was shown to have the most stable structure. Using surface plasmon 
resonance technology aptamer binding was tested and binding kinetics was determined. Five 
aptamers (B11, B19, B84, B65 and B5) raised against gp120 derived from a subtype B isolate 
called HIV-1BA-L were tested for binding to monomeric HIV-1DU151 gp120. Kinetic analysis 
of B11, B65 and B84 followed. The remaining three aptamers (P10, P2 and T58) were raised 
against whole HIV-1CAP45 pseudovirus and were tested for binding on monomeric HIV-1CAP45 
gp120. All three were used for binding kinetic assessment on monomeric HIV-1CAP45 gp120. 
The dissociation constants were found to be similar to that of previously characterised anti-
gp120 aptamers within the nanomolar range of 16.9 nM to 221 nM. Using the dissociation 
constant and predicted structure, P2 and B84 were identified as having the greatest potential 
for further characterisation. 
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1 Introduction 
 
1.1. Background 
Human immunodeficiency virus (HIV) infects an estimated 33 million people worldwide 
(UNAIDS 2009) and is the causative agent of acquired immunodeficiency syndrome (AIDS), 
a global public health issue. To date numerous treatments are available that can effectively 
increase the life expectancy of an infected individual. Most antiretroviral treatments, both in 
development and on the market, are based on HIV subtype B. However, HIV subtype C is the 
most prevalent subtype in developing countries and is responsible for the majority of the 
epidemic (UNAIDS 2009). With the prevalence of non-subtype B variants and the rapid 
mutation rate of the virus, resistance to treatment is experienced within a couple of years 
causing a change in treatment plan. It has been shown that treatment naive individuals may be 
infected with non-subtype B strains exhibit mutations that may reduce the efficacy of current  
treatments (Vergne 2000). These mutations may result in individuals developing multidrug 
resistance faster than expected. 
To combat drug resistance current treatment makes use of combinations of drugs to 
suppress viral replication - this is referred to as highly active retroviral therapy (HAART). 
The current antiretroviral drugs (ARVs) form four different classes based on their mode of 
action. This includes: protease inhibitors (PI), nucleoside and non-nucleoside reverse 
transcriptase inhibitors (NRTI and NNRTI), integrase inhibitors (II) and entry inhibitors (EI). 
HAART includes the use of a protease inhibitor (PI) coupled with either nucleoside reverse 
transcriptase inhibitors (NRTI) or non-nucleoside reverse transcriptase inhibitors (NNRTI) 
(Baxter 2006). Although this greatly increased the treatment success, the drugs still have to 
be altered over time to combat viral resistance and minimise toxic side effects (Hammer 
2008). Although, life expectancy of infected individuals is increased, the side effects of 
ARVs can affect the quality of life. This in turn affects the level of compliance to treatment, 
which requires over 95% compliance for successful treatment (Penedoa 2003). Other limiting 
factors include viral resistance (which can result in cross-resistance across an entire class of 
ARVs) and the cost of treatment (Baxter 2006; Reviewed in Stenger 2009). Thus there is a 
need for a novel HIV treatment option with reduced side effects and which is also cost 
effective. Aptamers, which are synthetic nucleic acid ligands, are being explored to meet 
these needs because they represent novel, non-toxic, non-immunogenic molecules that can be 
directed to bind a variety of targets with great specificity.  
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1.2. HIV Tropism and Entry  
The HIV-1 envelope glycoproteins are produced from a gp160 precursor protein and are 
targeted by antiviral therapies. The gp160 protein is extensively glycosylated and 
proteolytically cleaved into two subunits by a cellular convertase (Montagnier 1985; Chan 
1997). The cleavage results in gp120, the surface subunit, and gp41, the transmembrane 
subunit. These subunits remain non-covalently associated as trimers on the surface of the 
virus (Gallo 2003; Liu 2008). Glycoprotein gp120 was identified to contain variable (V1-V5) 
regions and four constant regions (C1-C4) (Starcich 1986). The viral envelope glycoproteins 
mediate viral entry into T lymphocytes and macrophages that  express CD4 and chemokine 
co-receptors (Reviewed by Urchil 2009). Co-receptors CCR5 and CXCR4 are differentially 
expressed on different CD4+ cells which defines their susceptibility to different HIV-1 
strains (Reviewed in Este 2007) (Figure 1).  
 
 
Figure 1: The Progression of HIV-1 Strains and Cellular Tropism.  
The choice of co-receptor is determined by the amino acid sequence of gp120. This determines cellular tropism as the co-
receptors are not universally expressed. R5 strains use CCR5 as a co-receptor and are associated with acute infection. X4 
strains use CXCR4 co-receptor and are associated with disease progression and onset of AIDS. Dual tropic strains (D) can 
use either co-receptor and show no phenotypic difference to individuals carrying both strains (M). (Adapted from Este 2007) 
 
The use of CCR5 and/or CXCR4 as a co-receptor is dependent on the amino acid 
sequence within the variable regions V3 and V1-V2 of gp120 (Chan 1999; Pastore 2006). 
Viral strains making use of different co-receptors have been isolated at different stages of the 
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disease. R5 strains (making use of CCR5 co-receptor) are preferentially transmitted and are 
associated with acute infections (Este 2007). X4 strains (making use of CXCR4 co-receptor) 
however, are associated with increased viral replication, faster disease progression, expanded 
cell tropism and the onset of AIDS (Reviewed in Biscone 2002; Este 2007). It is still unclear 
whether a change from R5 to X4 tropism is the cause or consequence of disease progression. 
Some strains can make use of both co-receptors and are termed dual tropic or R5/X4. 
Regardless of co-receptor used, HIV entry into human cells requires the following steps in 
sequence (Reviewed in Gallo 2003; Morris 2005): HIV surface glycoprotein gp120 binds the 
CD4 receptor on the surface of the host cell; this causes an outward rotation and displacement 
of each gp120 monomer (Liu 2008) and exposes gp41; gp120 binds a co-receptor, either 
CCR5 or CXCR4; gp41 penetrates the cell membrane and promotes membrane fusion; finally 
the viral core enters the cell (Figure 2). 
 
 
Figure 2: HIV Entry into CD4+ Cells. 
Figure illustrates the interaction between viral glycoproteins and cell surface receptors. Special attention is paid to the 
conformational change seen in gp120 (red) after binding CD4 and the subsequent exposure of gp41 (green). The roles of 
gp120 and gp41 in the binding of host and viral membranes are shown. 
 
Under native, non-binding conditions, the fusion proteins of gp41 are covered by gp120. This 
serves to reduce immunogenicity by restricting conserved epitopes from eliciting antibodies. 
It also reduces antigenicity by preventing elicited antibodies from binding to conserved 
regions (Zwick 2004). After the attachment of gp120 to CD4, gp41 undergoes a 
conformational change to a fusion active state that exposes the fusion peptide and N-HR (N 
terminal portion of the external domain), Figure 3, (Zwick 2004). During this stage, gp41 is 
most vulnerable but is limited by the short time period required for binding (Frey 2008). The 
conformational changes of gp41 allow for the insertion of the fusion peptide into the host cell 
and the generation of a pre-hairpin intermediate (Biscone 2002; Gallo 2003; Zwick 2004). 
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Once gp120 has dissociated from gp41, it forms a six-helix bundle which promotes 
membrane fusion (Weissenhorn 1997). The six-helix bundle is formed by the C terminal 
portion of gp41 (C-HR) and the N-HR in an anti-parallel conformation. This promotes 
complete fusion of the virus to the host cell and results in the fusion peptide and 
transmembrane segment of gp41 lying in parallel.   
Each protein plays an invaluable role in the fusion of the viral and host membranes. 
Molecules can be directed towards the glycoproteins or the cellular receptor proteins and 
inhibit their interaction and the subsequent entry of HIV into CD4+ cells. Treatments that 
block HIV fusion and entry are termed Entry Inhibitors. Both viral and host proteins involved 
in membrane fusion are potential targets for antiviral agents.  
 
 
Figure 3: Model of HIV Membrane Fusion. 
 Under native conditions gp120 and gp41 form a non-covalent association as a trimer. This conformation masks gp41 and in 
doing so reduces its antigenicity and immunogenicity. Upon binding to CD4, a conformational change in gp120 exposes 
gp41 (specifically the fusion peptide and N-HR). The N-HR positions the fusion peptide to bind to the host cell membrane. 
Binding generates a pre-hairpin intermediate in which gp41 is most vulnerable. Conformational changes caused by co-
receptor binding align C-HR in anti-parallel to N-HR in a six-helix bundle (hairpin). This process can be inhibited by C-HR 
peptides. The formation of the hairpin promotes membrane fusion. (Adapted from Chan 1998) 
 
1.3. Entry inhibitors 
With the increased knowledge on the entry mechanisms of HIV, each step has been studied in 
detail to design fusion and entry inhibitors. To date only two entry inhibitors have been 
approved by the American Food and Drug Administration (FDA). Enfuvirtide also known as 
Fuzeon or T20, was approved in 2003 making it the first entry inhibitor on the market 
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(Reviewed in Robertson 2003; Briz 2006). Peptides corresponding to the N-HR and C-HR 
were found to  inhibit HIV-1 entry into cells (Wild 1992; Wild 1994; Reviewed in Zwick 
2004). Consequently, T20 and T21 were developed and corresponded to the C-HR and N-
HR, respectively. Fuzeon (T20) is directed against gp41 C-HR and prevents the formation of 
the six-helix bundle. T20 was also found to prevent apoptosis of bystander cells by HIV 
membrane expressing cells (Meissner 2006). Problems have been noted with Enfuvirtide that 
correspond to its peptide nature. These include: high production cost, frequent injection site 
reactions (rarely treatment limiting), relatively short half life, poor distribution in the body, 
susceptibility to enzyme degradation and rapid renal clearance (Reviewed by Zwick 2004; 
Este 2007; Jacobs 2008). 
In 2007, Selzentry (Maraviroc) was approved and became the first oral entry inhibitor 
(Flexner 2007). Selzentry is a CCR5 antagonist that prevents co-receptor binding and blocks 
intracellular calcium redistribution and CCR5 signalling events after chemokine binding 
(Dorr 2005; Reviewed in Este 2007). Like other CCR5 co-receptor antagonist therapies in 
development, Selzentry has little to no effect on variant strains that use the CXCR4 co-
receptor or have dual tropism (Briz 2006; Flexner 2007). HIV evolves from using CCR5 to 
CXCR4 co-receptor with progression to AIDS (Biscone 2002). Due to this, the use of a 
CCR5 antagonist could select for the evolution of X4 strains which, due to their association 
with disease progression, would not be advantageous (Biscone 2002).  
Molecules targeting CXCR4 have been shown to have antiviral activity. Since the 
first CXCR4 antagonist, a limited number of agents have entered clinical trials, however most 
have failed (Reviewed in Este 2007). Poor reduction in viral load has been witnessed with the 
assessment of CXCR4 antagonists and an induced shift from X4 to R5 variants was seen 
(Este 1999). This highlights the need for a clearer understanding of the tropism switch and 
co-receptor usage. More recently, AMD11070 was found to be orally bioavailable but clinical 
trials have since stalled as histological changes in the liver were observed in animal trials 
(Moyle 2009). 
Even though only two entry inhibitors are on the market, many others are in 
development (Table 1). An overwhelming majority of entry inhibitors in development target 
the CCR5 co-receptor with only one targeting the virus (Table 1). Bearing in mind the 
trepidation associated with targeting CCR5 and the possibility that this may cause a co-
receptor switch, there is a need for additional treatments with alternative targets. 
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Table 1: Antiretroviral Drugs in Development During 2009.  
 
Name  Target Sponsor Status 
Vicriviroc  
(SCH417690, 
Schering D) 
CCR5 Blocker Schering Phase III 
TNX-355 
 (Ibalizumab)  
CD4 Blocker 
 (Monoclonal 
Antibody) 
TaiMed Phase II 
PRO 140* CCR5 Blocker Progenics Phase II 
INCB9471 CCR5 Blocker Incyte Corporation End Phase II¥  
AK602 CCR5 Blocker Kumamoto University, 
Japan 
Early Human Trials 
AMD070 CXCR4 Blocker AnorMed On Hold§ 
BMS-378806# gp120 Bristol-Meyers Squibb Phase I 
GSK 706769 CCR5 Blocker GlaxoSmithKline Phase II 
HGS004 CCR5 Blocker 
(Monoclonal Antibody) 
Human Genome 
Sciences 
Phase II 
PF-232798 CCR5 Blocker Pfizer Phase II 
SCH532706 CCR5 Blocker Schering Phase I 
SP01A CCR5 and CXCR4 
Blocker¤ 
Samaritan 
Pharmaceuticals 
Phase III 
TBR-652 CCR5 Blocker Tobira Therapeutics Phase II 
VCH-286 CCR5 Blocker ViroChem Pharma Phase II 
TAK-652 CCR5 Blocker Takeda Phase II 
*PRO 140 has been granted fast-track status by the FDA 
¥Incyte Corporation to license INCB9471 to another company for completion 
§ Development on hold due to liver problems in animal studies 
# BMS-378806 is being investigated for its use as a microbicide for the treatment of HIV subtype B (both CXCR4 and 
CCR5) 
¤ Reduces intracellular cholesterol and corticosteroid biosynthesis which disrupts the assembly of lipid rafts in cellular 
membranes 
(Taken in part from the 2009 Pipeline Report by Treatment Action Group (TAG) (www.treatmentactiongroup.org) and Fact 
Sheet 460 (revised September 2009))  
 
Entry inhibitors being a new class of antiviral therapy may present hope to individuals with 
HIV strains resistant to other ARVs such as protease and reverse transcriptase inhibitors. 
Numerous entry inhibitors have been designed, most of which comprised peptides or 
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antibodies. Aptamers can be developed to bind the glycoproteins involved in HIV entry and 
fusion. This may provide a novel approach to inhibition of membrane fusion and viral entry.  
1.4. Aptamers: A Novel Inhibitory Mechanism 
Aptamers are artificial nucleic acid molecules that can be engineered to bind specifically and 
with high affinity to a particular macromolecule (Reviewed in Ulrich 2006; Yan 2009). 
Single stranded nucleic acid molecules (RNA and DNA) fold to form complex tertiary 
structures which interact with cellular proteins and other ligands (Zhang 2004). The selection 
and design of highly selective aptamers with high affinity to their target has lead to the 
development of a variety of aptamers capable of binding a multitude of molecules.  
The pioneering work, in 1990, by the Gold and Szostak groups (Ellington 1990; 
Teurk 1990) identified an in vitro method for the selection of aptamers specific to organic 
dyes and T4 DNA polymerases. This method called the systematic evolution of ligands by 
exponential enrichment (SELEX (Figure 4)) is still in use today and has been adapted to 
streamline the processes of selection and isolation of aptamers.  
 
 
Figure 4: In vitro Selection of Aptamers Using SELEX.  
A random DNA oligonucleotides library is used for the production of DNA aptamers and can be transcribed into an RNA 
library. The oligonucleotide library is incubated with the target molecule. The bound oligonucleotides are partitioned from 
the unbound and partially bound oligonucleotides. This is an essential step for the selection of aptamers with the highest 
binding affinity. The bound oligonucleotides are eluted and amplified. This is an enriched pool of selected oligonucleotides 
which is again added to the reaction with the target for further selection. Rounds of selection and amplification proceed until 
high affinity aptamers are isolated. These can then be used for downstream applications and studies. 
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SELEX starts with a library of DNA or RNA that is incubated with a target molecule. 
The bound and unbound molecules are partitioned and the bound molecules are amplified by 
PCR (Sampson 2003). The library is synthesised chemically with each strand made up of a 
random region (typically 40 nucleotides) flanked by a fixed sequence (Zhang 2004). The 
fixed flanking sequences are typically identified by the polymerases used in the process and 
are invaluable in the selection process. By increasing the random region, the complexity of 
the library is increased (Zhang 2004) as this allows for increased diversity in the aptamer 
structures. With a 40 nucleotide random region, the DNA / RNA library can theoretically be 
composed of 1024 distinct molecules with as many different structures.  
Cycles of selection and amplification are continued until one or a small pool of 
aptamers that strongly interact with the protein are selected (Sampson 2003; Yang 2007). A 
number of non-specific binders can be selected due to non-specific protein interactions and 
the selection process may not remove all the non bound sequences (this is termed background 
partitioning) (Djordjevic 2007). For this reason a large number of non-specific sequences can 
be selected in the first couple of rounds. Thus, a number of selection and amplification cycles 
are required to reduce the effect of background partitioning on the selection of a high affinity 
binder.  
Many applications of the SELEX method have been developed that attempt to 
increase selectivity while decreasing selection time (Djordjevic 2007; Stoltenburg 2007; 
Yang 2007; Wei 2009). The chemical synthesis of aptamers results in little to no batch 
variation (O'Sullivan 2002). This is a great advantage of aptamer technology for therapeutic 
application as it implies an inherent quality standard that is not matched by other molecules. 
1.4.1. Aptamers vs. Antibodies 
Due to the severity of HIV as a global health problem, there is investigation into numerous 
types of prevention and treatment. Entry inhibitors have been identified as a potential 
strategy, not only as a treatment but as prophylactic as well. The potential of antibodies for 
this has been widely investigated. During the course of HIV infection, antibodies are raised 
against epitopes on gp120 (Stamatatos 2009). These are generally not conserved and lead to 
transient inhibition before the generation of escape mutants (Kelker 2010). It has been 
identified that to develop a successful antibody based vaccine for HIV it must encompass 
both broadly neutralising antibodies (NAbs) and an HIV specific T cell response (Phogat 
2007). Due to their immunogenic properties and involvement in HIV entry, the surface 
glycoproteins are a major target for the development of NAbs. NAbs have been developed to 
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a variety of HIV epitopes with varied success (Zwick 2001; Gorny 2002; Raja 2003; Mello 
2005; Miller 2005). NAbs represent a possible vaccination option, however, their use is not 
without problems.    
Aptamers have advantages over their antibody counterparts on a number of levels. 
Preparation of aptamers is faster and simpler than that of antibodies which would allow for 
easier scale up of production. Aptamers have the same or higher affinity with their targets 
than antibodies and usually show dissociation constants ranging from low picomolar to low 
nanomolar (O'Sullivan 2002; Zhang 2004). Strong binding affinity to a target molecule is 
essential if an aptamer is to be used for efficient and effective drug delivery. Binding affinity 
represented by the dissociation constant provides information regarding binding strength and 
stability of two molecules. The lower the dissociation constant, the tighter the binding and the 
less the molecules tend towards being apart. Thus, the best candidate for pharmaceutical 
application would have a low dissociation constant and a high specificity to the target. In a 
contrasting theoretical study by Eaton et al (1995) suggested that a tight and specific binding 
aptamer may be affected more readily by mutations within the binding site. A strong binding 
affinity within a very small region may be more susceptible to minor changes in amino acid 
sequence or protein conformation and thus may not be the best candidate (Eaton 1995). 
Although these conclusions have been refuted by the identification of aptamers that can 
neutralise more than one strain of HIV (by binding to gp120) it is worth noting. 
Aptamers have been shown to be able to discriminate between targets with subtle 
structural differences such as isoforms of a protein (Jenison 1994; Gopinath 2006). This is an 
invaluable characteristic when dealing with a pharmaceutical as it would enable the aptamer 
to distinguish between healthy and disease cells even when the difference is minor. As 
testament to their high binding specificity, aptamers have been selected for use in affinity 
chromatography as affinity ligands (Hage 1999).  By making use of this characteristic, 
biomarkers for disease conditions have been identified using aptamers. Aptamer-facilitated 
biomarker discovery (AptaBiD) has been shown to overcome the major problems previously 
encountered with biomarker discovery  such as false positives and false negatives due to 
sample processing and differences in localisation and modification of proteins (Berezovski 
2008). Berezovski et al (2008) successfully identified biomarkers for immature and mature 
dentritic cells. They went further to highlight how the aptamers used could have far reaching 
applications including targeted delivery of therapeutics, cell visualisation, tracking cells in 
vivo and as drug candidates themselves.  
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Aptamers can be selected to bind a wide range of macromolecules including those 
that have low immunogenicity or are toxic substances (O'Sullivan 2002; Wei 2009). 
Antibodies are limited by the immunogenicity of their targets. However a recent publication 
highlighted a method for eliciting antibodies to conserved and non immunogenic epitopes 
with the aid of multi copy proteins (MCP) (Kelker 2010). Aptamers are more stable than 
antibodies and can be stored long term at ambient temperature (Wei 2009). Denatured 
aptamers can be regenerated while antibodies have a short life span and cannot be 
regenerated after denaturation. Aptamers are able to discriminate between targets based on 
subtle structural changes such as the presence or absence of a methyl or hydroxyl group 
(O'Sullivan 2002). Due to their high specificity, aptamers can be directed against highly 
specific targets. This has been applied to a wide range of therapeutics, specifically for cancer 
treatment. Aptamers can be used to transport inhibitory molecules to specific cells reducing 
the off target effects seen in current treatment. Studies have looked at chemically binding or 
co-synthesising aptamers and siRNA so that they can be selectively targeted to cells 
expressing relevant receptors (Reviewed in Castanotto 2009). 
1.4.2. Current and Future Prospects of Aptamer Technology 
Aptamer research encompasses a wide range of fields. Their high specificity and small size 
makes them ideal for use in analytical, therapeutic and diagnostic applications. Aptamers 
have been developed against various HIV components including: gp120 (Khati 2003), 
Integrase (de Soultrait 2002), Reverse-Transcriptase (Andreola 2001) and the trans-activation 
response (TAR) RNA (Duconge 1999). Aptamers have also been raised against drug resistant 
strains of HIV in an attempt to overcome challenges associated with drug resistance (Li 
2008). There is potential for aptamer mediated treatment of HIV at many levels. When 
targeting gp120, aptamers can be designed for use as entry inhibitors. A major challenge 
when working with gp120 is its probable unstable conformation and the large conformational 
change seen when gp120 binds CD4 (Kelker 2010). In addition, gp120 is mostly shielded 
from immune response by a cover of negatively charged carbohydrate groups (Sayer 2002). 
These inhibit the binding of molecules not only by reducing immunogenicity but by steric 
hindrance of immunogenic epitopes on the gp120 molecule. Aptamers are small enough to 
not be affected by steric hindrance of the gp120 molecule increasing the epitopes available to 
them. By identifying the minimal sequence required for its binding, an aptamer can be 
reduced in size to contain only the essential binding sequence (Dey 2005). This would further 
limit the effects of steric hindrance against aptamer binding. 
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A range of aptamers have been developed that bind within the CCR5 binding region 
of the gp120 molecule and effectively block HIV binding to the cell surface (Sayer 2002; 
Khati 2003; Dey 2005; Cohen 2008). Specific examples of such aptamers are those described 
by Khati et al (2003) that were selected for their ability to bind gp120 of HIV-1Ba-L. Some of 
the aptamers selected were found to bind within the conserved CCR5 binding region of 
gp120 and neutralise HIV infectivity.  HIV-1Ba-L is a subtype B virus that is not prominent 
outside of the Americas, Europe and Australasia and so further study included neutralisation 
test on other variants in which some aptamers were successful (Khati 2003). One aptamer 
highlighted by Khati (2003), B40, has subsequently been highly characterised and tested 
against other strains of HIV. A synthesised version of the B40 aptamer is now commercially 
available for laboratory use as UCLA (Cohen 2008).  
Some of the aptamers used in this study were identified in the same study as B40 but 
have not been as highly characterised.  These aptamers were raised against monomeric gp120 
which is not its natural state. The other set of aptamers used in this study were raised against 
HIV-1CAP45 (a subtype C virus) pseudovirus expressing the whole glycoprotein complex. This 
is a better representation of the gp120 encountered if used as a therapeutic agent. Both sets of 
aptamers were tested on a subtype C gp120 as subtype C is the most predominant subtype. In 
2004, subtype C HIV was responsible for more than 50% of all infections worldwide 
(Hemelaar J. 2006). Aptamers may provide a novel treatment for HIV infection and rival the 
numerous antiviral therapies currently available as well as those in development. 
To date, only one aptamer based therapeutic has been approved by the FDA and is on 
the market. In 2004, Macugen (Pegaptanib) was approved to slow vision loss due to all 
subtypes of neovascular age-related macular degeneration (AMD) (Gragoudas 2004; Nowak 
2006). Previous studies identified angiogenesis as the underlying cause of AMD which is 
regulated by many factors and isoforms (Eugene 2005). Macugen targets VEGF165 (vascular 
endothelial growth factor) and successfully treats AMD by targeting the underlying cause 
(Gragoudas 2004). 
For future aptamer mediated therapies a number of obstacles must be considered. A 
key problem facing the use of aptamers in vivo is their rapid degradation and clearance from 
the body. Within biological fluids, aptamers are susceptible to nuclease degradation rendering 
them ineffective. Although many of the solutions to nuclease degradation were provided over 
10 years ago, it still comes up as an important consideration in aptamer design. The numerous 
methods identified to circumvent this problem make use of the fact that nuclease activity 
relies on the ribose 2′-OH group and modification of this can significantly decrease nuclease 
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activity (Zhang 2004). However, modification of the aptamer 2′ end must take into 
consideration the enzymes used in SELEX and must not disrupt their functioning. 
Modifications such as adding an amino (NH2), fluoro (F) or 2′-O-alkyl  group to the 2′ end do  
not interfere with the SELEX enzymes and increase nuclease resistance by as much as 1000-
fold (Osborne 1997; Zhang 2004). Other modifications such as adding a benzoyl group at the 
C5 position, using phosphorothioated oligonucleotides and replacing D-ribose with L-ribose 
(Spiegelmers method) and using locked nucleic acids in aptamer design (Darfeuille 2004) 
have shown to increase nuclease resistance (Zhang 2004). Most recently the production of a 
circular RNA aptamer was reported by Umekage and Kikuchi. This aptamer not only retained 
its binding properties after purification but avoided exonuclease-induced degradation in vivo  
and in vitro increasing the half life by 30 -fold (Umekage 2009). This method eliminates the 
need for 2′ modifications which can affect ligand specific binding ability (Umekage 2009). 
Although this method protects the aptamer against exonuclease mediated degradation, the 
circular aptamers were degraded in human sera. This was attributed to RNase A-like activity 
(although the precise causative agent is still unknown) (Umekage 2009). Although not 
flawless, this method of production created new options for aptamer design. With the 
availability of many techniques for reduced susceptibility, one can focus more on the 
problems of bioavailability and delivery of aptamer therapeutics. Currently aptamer based 
therapies are delivered via injection; there is hope that future technology may allow for oral 
or dermal application.  
Another setback of aptamer therapy is its bioavailability. Aptamers, ranging from 8-
15 kDa, are roughly one tenth the size of antibodies (155 kDa) (Zhang 2004).  With such 
small size, aptamers are rapidly removed from the blood and cleared from the body (Zhang 
2004) thus reducing bioavailability. To circumvent this, aptamers are conjugated to high 
molecular weight molecules such as polyethylene glycol (PEG), streptavidin or to the surface 
of liposomes or nanoparticles (James 2001; Zhang 2004). This problem highlights the 
importance of adequate kinetic analysis of potential aptamers. The aptamers identified by 
Khati (2003) were identified with numerous applications in mind. One of which was for them 
to act as entry inhibitors for HIV-1 as they bind to gp120 and thus inhibit binding of HIV to 
target cells. For this application to be successful, the aptamer would have to bind to the gp120 
molecule with great affinity and have a low dissociation constant.  The aptamer that has a 
sufficiently low dissociation constant and sufficiently high target affinity would bind the 
target molecule quickly and for long enough to increase bioavailability. Kinetic data could 
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then be used for the selection of aptamers with the potential for downstream applications such 
as a carrier and / or targeting molecule. 
1.4.3. Application of Aptamer Technology: Delivery of siRNA 
An aptamer that binds gp120 with high affinity would open the door for numerous 
therapeutic applications such as: directly inhibiting HIV-1 entry or transporting other 
inhibitory molecules (Cohen 2008; Xiao 2008). Aptamers have been previously used as 
targeting molecules for cancer treatment, this technology has application in numerous 
diseases (Dhar 2008). Another example is the use of aptamers to transport and deposit 
siRNA, capable of inhibiting the HIV, into an infected cell (Zhou 2009). In this way, cells 
that have been previously infected by HIV can be selectively targeted by the RNA 
interference (RNAi) therapy.   
RNAi is a conserved gene silencing pathway that makes use of a double stranded 
RNA trigger and a range of cleavage and recognition proteins  (Saayman 2008; reviewed by 
Siomi 2009). This gene silencing pathway has been exploited for the generation of numerous 
therapeutics suppressing viral genes or rouge cellular genes (reviewed in Boutros 2008). 
RNAi is an ATP-dependent and transcription-independent mechanism of gene silencing that 
occurs post transcriptionally in the cytoplasm (Chen 2008).  
Genes can be silenced by degradation of mRNA inhibiting the production of the gene 
product. This is mediated in a homology dependent manner by siRNA, a 9-24 base pair 
double stranded RNA molecule with a two nucleotide 3′ overhang (Chen 2008). Briefly, the 
RNAi machinery recognises the siRNA by its overhang and cleaves it. The short double 
stranded RNA molecules generated by cleavage, directs the degradation of mRNA molecules 
that are of perfect or near-perfect homology (Chen 2008). Constanotto (2009) provides a 
clear overview of the mechanisms of gene silencing by siRNA. siRNA has been used in 
therapies for a wide range of diseases and infections, some of which include: hepatitis B and 
C virus (Arbuthnot 2007; Chen 2008), neurodegenerative disorders (Weinberg 2009) and 
HIV (Cave 2006; Barichievy 2007). By coupling the direct targeting of aptamers with the 
strong inhibitory effect of siRNA, a promising anti-HIV treatment could be developed.  
1.5. Problem Identification 
Prior to any downstream applications, a sound knowledge of the aptamer binding kinetics is 
essential.  It is for this reason that this project determined gp120 binding kinetics for a group 
of aptamers previously identified by Khati (2003) and a group of aptamers raised against 
trimeric HIV-1CAP45 gp120 (Grace London, unpublished data). Much like B40, these 
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aptamers too could represent good candidates for therapeutic applications. The kinetic 
analysis of this project will aid in the identification of these molecules as possible leads.  
1.6. Research Objectives 
The primary objective of this study was to characterise selected aptamers and determine their 
binding kinetics to subtype C gp120. 
 
Secondary objectives were: 
1. To in vitro transcribe a selected number of monoclonal aptamers isolated against 
monomeric HIV-1Ba-L gp120 and HIV-1CAP45 Env pseudovirus, respectively 
 
2. To screen these aptamers for binding to HIV-1DU151 and HIV-1CAP45 monomeric 
gp120 and determine their kinetics 
 
3. To determine the secondary structure of the selected aptamers 
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2 Methods 
 
2.1. Cell Maintenance 
293T mammalian cells (Invitrogen) were seeded at a density of 5 × 105 cells/ml. The cells 
were maintained in 15 ml Dulbecco’s Modified Eagle’s Medium (DMEM), 10% Foetal Calf 
Serum (FCS), 50 mg/L gentamicin, 0.25% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES)) in a humidified incubator with 5% CO2 at 37 °C. 
 
2.2. Selection of Aptamers 
The aptamers used in this research were raised against two different proteins. One set, (B19, 
B11, B65, B5 and B84) identified by Khati (2003) were raised against monomeric gp120 
from a subtype B virus called HIV-1Ba-L. The other set (P2, P10 and T58) were isolated 
against whole subtype C HIV-1CAP45 pseudotype virus (Grace London, unpublished data). 
UCLA, which is a shortened synthetic derivative of the B40 aptamer, was used for 
comparison and as a positive control.  
B19 was selected because it neutralises HIV-1Ba-L but does not bind within the CD4 
epitope of gp120. B65 is very short and neutralises HIV-1Ba-L. B84 and B11 were shown to 
be very strong neutralisers of HIV-1Ba-L. B5 was shown not to neutralise HIV-1Ba-L but was 
included to compare the binding kinetics with the good neutralising aptamers. Since 
monomeric gp120 is not present on native HIV aptamers selected against trimeric gp120 
were chosen because they were expected to show better binding and neutralisation of the 
virus. P2, P10 and T58 aptamers were selected for binding to the whole CAP45 glycoprotein 
(including gp120 trimer and gp41). All these aptamers bind gp120 CAP45 and neutralised 
HIV-1CAP45 (Grace London, unpublished data). These aptamers were selected for kinetic 
analysis due to their strong binding and neutralisation properties. 
 
2.3. Oligonucleotides 
The aptamers used in this research were generated by in vitro transcription of the Polymerase 
Chain Reaction (PCR) product from the plasmid DNA. Each aptamer is made up of the same 
T7 and T3 SELEX primers flanking randomized nucleotides. This allows for aptamers with 
different binding properties and structural characteristics from within the same pool. The 
aptamers sequences can be seen in the table below (listed 5′ → 3′).  
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Table 2: Nucleotide Sequences of the Common Flanking Regions (T7 and T3) and 
Random Internal Regions of the Selected Aptamers. 
 
Sequence name Sequence
T7 SELEX primer TAATACGACTCACTATAGGGAGACAAGACUAGACGCUCAA 
T3 SELEX primer UUGACAUGAGACUCACAACAGUUCCCUUUAGUGAGGGUUAAUU 
B19 AGACCUUAUACCUGAGAUUACACGCUCUUCGAGCACGUCGAC 
B65 GAACACCAUCGG 
B84 AUGACGUACCCGCACAAGCCACCACAAGUCUUAAUCGCGCCACCCUUGC 
B5 GGGCGCUUAAUGUAUGCCGUAUGACCCUCAACAUCCGACUCAGUUAAGC 
B11 CCAAGGGCUAAGUCCGCAAAUAUCCUUCCUAAAGGACUCGUUACGUCGG 
P10 AGUAGUCGAUGGGAUUGCUAGGCCGGUCAUCAUGAAAACGAAGUCGA 
T58 CAAAUCAUUUCCAAUAAGGGGAGUACUAAGAGGCCAUUCAAAAAACGAAA 
P2 AUUUGAAGUCGGUGGCAAGAUGGUGCGCUCAUGAAGGCAUCUUCGG 
* T7 SELEX primer includes the T7 promoter sequence which is not transcribed; this is seen in bold and underlined (the 
promoter sequence is in DNA however, the remaining sequence is displayed as transcribed RNA). 
 
2.4. Polymerase Chain Reaction 
Plasmid DNA of each aptamer had to be amplified before in vitro transcription; this was 
achieved using polymerase chain reaction (PCR). Each 100 µl reaction mixture contained 1 × 
Taq buffer (Promega), 1 mM MgCl2 (Promega), 0.2 mM dNTPs (Fermentas), 1 µM T3 and 
T7 primer (Inqaba Biotech), 1 U Go Taq Polymerase (Promega) and 100 ng DNA. A twenty 
eight cycle PCR was performed with the following parameters: 93 °C for 30 seconds for 
denaturation, 72 °C for 1 minute for annealing and 72 °C for 8 minutes for extension.  
  The PCR product was cleaned by centrifugation using a PCR purification kit 
(Promega Wizard). PCR product was prepared for clean up by adding equal volume 
Membrane Binding Solution. One SV mini-column was placed in a Collection Tube for each 
PCR product to which the PCR product-Membrane Binding Solution was added and 
incubated for 1 minute. The SV mini-column assembly was centrifuged at 16 000 × g for one 
minute after which the liquid in the collection tube was discarded. The SV mini-column was 
returned to the collection tube and was washed with 700 µl Membrane Wash Solution 
(previously diluted with 95% Ethanol). The SV mini-column assembly was again centrifuged 
at 16 000 × g for 1 minute. The collection tube was emptied and the SV mini-column was 
returned. The wash was repeated with 500 µl of Membrane Wash Solution and centrifuged at 
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16 000 × g for 5 minutes. The collection tube was again emptied and the SV mini-column 
returned. The assembly was centrifuged at 16 000 × g for 1 minute to evaporate remaining 
ethanol. The SV mini-column was then transferred to a 1.5 ml microfuge tube and 50 µl 
nuclease-free water was added to the centre of the column. The assembly was incubated at 
room temperature for 1 minute before centrifugation at 16 000 × g for 1 minute. The 
microfuge tube then contained the purified DNA and the SV mini-column was discarded. 
DNA quantification was obtained using a NanoDrop-spectrophotometer at A260.  
Fractions of the clean DNA were resolved on a 2.5% agarose gel (containing 5% Ethidium 
Bromide) in 1 × TBE running buffer. The DNA was visualised under UV light. A Mass Ruler 
Low Range DNA Ladder (Fermentas) was used for DNA sizing and quantification by 
Molecular Imager Chemidoc XRS+ Imaging System (BIORAD). DNA was retained for RNA 
aptamer production by in vitro transcription. 
 
2.5. In vitro Transcription 
In vitro transcription was done as previously described (Khati et al.  2003).  Briefly,  100 µl 
reaction mixtures contained: 1.5 ng DNA, 1 × transcription buffer (New England Biolabs, 
40 mM Tris-HCl, 6 mM MgCl2, 10 mM Dithiothreitol, 2 mM spermidine), 2 mM spermidine, 
1 mM rATP, 1 mM rGTP, 1.5 mM 2′F CTP, 1.5 mM 2′F UTP (Fermentas), 2 U T7 RNA 
Polymerase (New England Biolabs). Transcription reaction was incubated overnight at 37 °C.  
Transcription was stopped with the addition of 1 U RNAse free DNAse I in 1 × 
Reaction Buffer (Fermentas, 100 mM Tris-HCl (pH 7.5 at 25°C), 25 mM MgCl2, 1 mM 
CaCl2) and incubated at 37 °C for 25 minutes. RNA was purified from low molecular weight 
contaminants on a 0.9 G50 column. The G50 column is made up of a 1 ml pipette tube loaded 
with Sephadex solution (6.5 % sephadex (w/v) suspended in 0.02% NaN3) and washed with 
150 mM NaCl. The transcription solution was incubated with 1% Phenol Red solution before 
being loaded to the column. Phenol red stains the free nucleotides which are retarded by the 
sephadex beads. The full length RNA was eluted first in a clear solution by the addition of 
600 µl 150 mM NaCl. This significantly reduces the concentration of the RNA in solution 
and thus RNA must be precipitated out. 
Purified RNA was precipitated in 5:1 phenol-chloroform-isoamyl alcohol pH 4.7 and 
extracted with chloroform. The extract was incubated at -80 °C for 2 hours in 0.1 Vol 3 M 
NaAc pH 5.2 and 1 Vol Isopropanol.  After incubation, it was centrifuged at 4 °C for 30 
minutes (190 × g). Supernatant was discarded and the pellet washed with 70% Ethanol. 
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Ethanol was removed and RNA was re-suspended in 50 µl nuclease-free water (Fermentas). 
RNA was quantified by spectrophotometry at A260. RNA fractions from each step were 
resolved on a 12% denaturing (8 M Urea) polyacrylamide gel (pre-run for 30 minutes at 200 
V), with 1 × TBE running buffer at 200 V for 45 minutes, to validate the process. Prior to 
running on a denaturing PAGE gel, RNA was incubated with 2 × RNA loading dye (95% 
formamide, 0.025% SDS, 0.025% bromophenol blue, 0.025% xylene cyanol FF, 0.025% 
ethidium bromide, 0.5 mM EDTA, Fermenas) and heated to 70 °C for 15 minutes. 
Visualisation was achieved under UV light by 0.1% (v/v) Ethidium Bromide staining. 
For the correct folding, aptamers were denatured at 95 °C for 4 minutes (incubated at 
room temperature for 4 minutes), refolded in the presence of 1 × HMKCN buffer (10 mM 
Hepes pH 7.4, 1 mM MgCl2, 1 mM CaCl2, 2.7 mM KCl, and 150 mM NaCl) and incubated at 
room temperature for 10 minutes prior to use. 
 
2.6. Expression of gp120  
HIV-1DU151 envelope glycoprotein gp120 was expressed and purified in 293T mammalian 
cell line,  using lipofection (Felgner 1987) to transfect the plasmid. Transfection followed the 
manufacturer’s protocol for FuGENE 6 Transfection Reagent (Roche). Briefly, 293T cells 
were seeded at a concentration of 1 × 106 cells/ml in a hyper flask in 50 ml DMEM10 
(dulbecco’s modified eagle’s medium, Invitrogen) (10% Foetal calf serum (Invitrogen), 2.6% 
HEPES (Invitrogen), 0.5% Gentomycin (Invitrogen)) and incubated at 37 °C in a humidified 
incubator with 5 % CO2 overnight. Transfection mixture (72 µl FuGENE, 25 µg DNA 15 ml 
serum free DMEM) was added to cells at 50% confluency. The transfection was incubated at 
37 °C in a humidified incubator with 5 % CO2 for 48 hours. Supernatant was harvested every 
48 hours until the monolayer of cells started to detach from the flask surface. Culture 
supernatant was centrifuged at 3900 × g for 10 minutes, filter sterilised through a 0.45 micron 
filter and stored at – 20 °C. 
 
2.7. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
The presence and purity of the desired protein was confirmed using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). Transfection supernatant was incubated 
with SDS-PAGE sample buffer (0.125 M Tris-HCl, 4% (w/v) SDS, 20% (v/v) glycerol, 5% 
(v/v) β-mercaptoethanol and 0.02% (w/v) bromophenol blue, pH 6.8) for 5 minutes at 95 °C. 
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These samples were resolved on an 8% SDS-PAGE gel at 150 V in 1× SDS-PAGE running 
buffer (25 mM Tris-HCl, 200 mM Glycine, 0.1% (w/v) SDS) to identify the presence of the 
desired protein. Full Range rainbow protein molecular weight marker (AEC-Amersham) was 
used as a standard. The gel was stained using coomassie Stain (40% methanol; 0.7% acetic 
acid; 0.075% coomassie dye) and destained with coomassie destain (40% methanol; 0.7% 
acetic acid). Purified protein was used for binding and kinetic experiments. 
 
2.8. Western Blot 
A western blot was used to confirm the protein presence. Protein was transferred to the 
nitrocellulose membrane at 4 °C overnight at 30 V in 1 × transfer buffer (50 mM Tris, 380 
mM glycine, 0.1% (w/v) SDS, 10% (v/v) methanol pH 8.3). After transfer to the 
nitrocellulose membrane, the membrane was blocked with 5% fat free powder milk in 
phosphate buffered saline, PBS, (1M KH2PO4, 1M K2HPO4, 5M NaCl in 1l) (Sigma-Aldrich) 
for 1 hour. After blocking, the membrane was probed with the 1:20 000 dilution of human 
serum from HIV-1 positive patients containing a high level of anti-HIV-1 gp120 antibodies in 
2.5% (w/v) fat free milk powder in PBS. 
After incubation with the primary antibody solution, the membrane was washed in 
0.05% PBS Tween-20 (0.01 M phosphate buffer, 0.0027 M KCl, 0.14 M NaCl, 0.05% 
Tween, pH 7.4 in 500 ml) (Sigma-Aldrich) solution three times for 10 minutes. The 0.05% 
PBS Tween-20 was removed and the membrane was incubated with 5% blocking buffer for 1 
hour. Blocking buffer was discarded and the membrane was incubated with the secondary 
antibody (goat-anti human 1: 20 000) (Kirkegaard & Perry Laboratories, Inc.) for 1 hour. 
Secondary antibody solution was discarded and the membrane was washed with 0.05% PBS 
Tween-20 three times for 10 minutes. The immunereactive bands were detected using an 
enhanced chemiluminescence detection system (Amersham Pharmacia Biotech) according to 
manufacturer’s protocol. A purified HIV-1ConC gp120 protein was included as a positive 
control.  
  
2.10. BIAcore Surface Plasmon Resonance Assays  
BIAcore 3000 (BIAcore AB Inc.) SPR assay, was used to determine the binding capacity and 
kinetics of each aptamer to gp120 and to ensure the correct structural conformation of bound 
gp120. Research grade CM5 chips, EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbindiimide 
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hydrochloride), NHS (N-Hydroxysuccinimide), Ethanolamine and HBS-N running buffer 
used in all the SPR experiments were obtained from BIAcore AB Inc. For the preparation of 
CM5 chips, 1 × HBS-N buffer (10 mM Hepes, 150 mM NaCl, pH 7.4) running buffer was 
injected at a flow rate of 10 µl/min. CM5 sensor chips were activated with 0.2 M EDC and 
0.5 M NHS for 10 minutes.  By amine coupling chemistry 20 000 response units (RU) gp120 
at 25 µg/ml (buffer exchanged in 10 mM NaAc) was immobilised to the experimental flow 
cell(s). A flow cell with no protein bound was included as a negative control. This allowed 
for the deduction of non-specific background binding during analysis. After protein 
immobilisation, remaining activated carboxymethyl groups were blocked by flowing 1 M 
Ethanolamine for 7 minutes. Non-specifically bound protein was removed with 10 mM 
Glycine-HCl injected for 3 minutes. Resultant sensorgrams were analysed using 
BIAevaluation 4.1 software (BIAcore AB Inc.). The negative control was either deducted 
from the experimental result to correct for non-specific binding or was included in the graphs 
as a point of reference. 
 
2.10.1. Validation of Protein Structure 
Monoclonal antibody b12 binding was used to determine if the protein produced was bound 
to the CM5 chips (for use on the BIAcore 3000, BIAcore AB Inc.) maintained the correct 
confirmation. The CM5 chip was prepared as indicated above (Section 2.10) with one 
experimental and one control flow cell. IgGb12 antibody (14 µg/ ml in 10 mM NaAc pH 5.0) 
was injected over the two flow cells for 5 minutes at a rate of 10 µl/ minute. The chip was 
regenerated with 20 nM NaOH injected for 1 minute. BIAevaluation software (BIAcore AB 
Inc.) was used to evaluate the binding of b12 monoclonal antibody to the protein. The 
negative flow cell results were deducted from the experimental results to adjust for non-
specific binding and instrument noise.  
 
2.10.2. Aptamer Binding to gp120 
Binding was assessed with 200 nM aptamers to 20 000 RU gp120.  Aptamers were denatured 
at 95 °C for 4 minutes and refolded using 1 × HMCKN buffer (10 mM Hepes pH 7.4, 1 mM 
MgCl2, 1 mM CaCl2, 2.7 mM KCl, 150 mM NaCl). Aptamers were incubated at room 
temperature for 6 minutes prior injection to ensure correct refolding.  Each aptamer was 
injected for 3 minutes at 10 µl/ minute. The chip was regenerated after injecting each aptamer 
with 20 nM NaOH injected for 1 minute.  
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2.10.3. Aptamer Binding Kinetics on gp120  
The binding kinetics of aptamers was determined using monomeric gp120.  The level of 
protein immobilised was optimised using 23 000 RU, 13 000 RU and 3000 RU of 
immobilised gp120 on three flow cells. A fourth flow cell with no protein immobilised was 
included as a negative control. Optimisation preceded experimentation as kinetics analysis 
requires a dose-dependent binding assay to determine mass transport limitations on kinetics. 
For the kinetic experiment 25 µg/ml gp120 was injected over three flow cells for 3 minutes at 
a flow rate of 10 µl/ minute. The three experimental flow cells served as triplicate kinetic 
analyses essential for the determination of a standard deviation of kinetic analysis. 
Aptamers were denatured at 95 °C for 4 minutes and refolded using 1 × HMCKN 
buffer (10 mM Hepes pH 7.4, 1 mM MgCl2, 1 mM CaCl2, 2.7 mM KCl, 150 mM NaCl). 
Aptamers were incubated at room temperature for 6 minutes before injection. Aptamers were 
injected at 70 µl/ minute in ascending concentration order (from 4.5 nM to 300 nM). The 
aptamers were injected using KINJECT with the dissociation time set to 600 seconds 
allowing for a contact time of 43 seconds. The chip was regenerated after each aptamer 
injection with 20 nM NaOH which removed the bound aptamer. 
Aptamer association rates (k(on)), dissociation rates (k(off)) and dissociation 
constants (Kd) were calculated with BIAevaluation 4.1 software (BIAcore AB Inc.) The 
goodness of fit was calculated based on an agreement between experimental data and 
calculated fits and was expressed as a Chi2 value less than 1. The kinetic parameters were 
analysed using the 1:1 Langmuir binding model initially calculated with the simultaneous ka / 
kd analysis tool and later with the separate ka / kd analysis tool. The separate ka / kd tool 
allowed the user more control over the analysis and produced more statistically relevant data 
(i.e. Chi square values were systematically closer to 1) although the resultant Kd in both cases 
were similar. The result for the empty flow cell was subtracted from the experimental flow 
cells to correct for refractive index changes due to non-specific associations and instrument 
noise. Kinetics on each flow cell individually was analysed individually. The results were 
examined together to produce a standard deviation for the calculated Kd. 
 
2.11. Computational Analysis of Aptamer Secondary Structure 
MFOLD (http://mfold.bioinfo.rpi.edu/) was used to computationally identify secondary 
structures possible within the aptamer using the sequence information (Zuker 2003). The 
nucleotide sequences were added in FASTA format as linear RNA molecules. Secondary 
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structure predictions were made at 37 °C with no divalent ions, 1M NaCl, 5% suboptimality, 
an upper limit of 50 computed folding, a maximum interior / bulge loop size of 30 bp and 
maximum asymmetry of interior / bulge loop of 30 bp. No limit was defined for the distance 
between base pairs and pnum values were included in the analysis outputs. A pnum value is 
assigned to each base in a structure and provides certainty for the prediction by indicating the 
number of different conformations that contain the same feature. 
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3 Results 
 
3.1. PCR of Aptamer Clones 
Aptamer clones were amplified by PCR to generate enough DNA for in vitro transcription. 
The amplified PCR product contained a T7 promoter sequence necessary for the transcription 
reaction that was introduced by the forward primer. The T7 promoter sequence was required 
for the activation of bacterial T7 polymerase, a DNA dependent RNA polymerase responsible 
for the conversion of the PCR product (DNA) to RNA aptamers. 
After PCR the DNA was resolved on a 2.5% agarose gel to verify the quality and 
visually quantify the DNA (Figure 5). The amplified sequences were expected to correspond 
to the number of bases shown in Table 3. Aptamer length varied according to the number of 
nucleotides incorporated into the variable region as the size of the flanking regions was 
consistent between aptamers.  
 
Table 3: Aptamer Sizes in Number of Bases 
 
Aptamer Name Number of Bases Aptamer Name Number of Bases 
B19 108 B5 115 
B65 78 P2 112 
B84 115 T58 116 
B11 115 P10 113 
 
  
Figure 5: 2.5% Agarose Gel of Representative PCR Products Used for Transcription.  
B19, B65 and B84 fragment sizes were determined using the molecular weight marker and corresponded to the expected 
fragment size. 
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Amplified DNA for aptamers B19, B65 and B84 resolved on a 2.5% agarose gel 
corresponded with the expected size of the aptamers (Figure 5 and Table 3). Artefacts on the 
gel could be due to incomplete amplification of the DNA (Figure 5). The correct sized band 
contained more DNA indicated by the relative brightness of the band. It was concluded that 
possible incomplete amplification would not compete with fully amplified stands during the 
transcription reaction due to their relative concentrations. 
3.2. In vitro Transcription of Aptamers 
To convert amplified DNA clones into RNA aptamers in vitro transcription was used. The 
DNA clones included a promoter sequence for a bacterial T7 polymerase. This DNA 
dependent RNA polymerase was responsible for the conversion of the PCR product (DNA) to 
RNA aptamers. During the in vitro transcription reaction fluoropyrimidines (cytosine and 
uracil) were incorporated into the aptamer structure to protect the RNA from nuclease 
degradation and make the RNA more stable.  
Denaturing PAGE of reaction aliquots from the transcription of B84 indicated that the 
transcription reaction had been successful (Figure 6). Denaturing PAGE shows high 
molecular weight RNA bands of the correct size indicating that correct sized fragment was 
transcribed (Figure 6). However, low molecular weight bands are seen in all reactions 
indicating that there may have been partial degradation of some DNA prior to transcription 
resulting in smaller fragments (Figure 6).  
 
Figure 6: Denaturing Polyacrylamide Gel Indicating the Process of RNA Purification 
and Precipitation.  
Molecular weight markers on either side of the gel were used to size the fragments. Before DNAse treatment has the highest 
intensity bands. After DNAse treatment, the bands are fainter. Purified RNA is the precipitated RNA after G50 purification. 
 
3.3. Computational Analysis of Aptamer Secondary Structure 
The secondary structure of the aptamers was predicted using MFOLD. MFOLD predicts the 
minimum free energy, ΔG, required for conformational stability at 37 °C (Zuker 2003).  For 
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each aptamer, between one and five conformations were predicted. P2 had five predicted 
stable structures, P10 had four, B65 and B11 had three, T58 and B19 had two and only one 
was predicted for B84 (Figure 7). A structure dot plot (Appendix 1) allowed for the 
comparison of structural similarities and differences to be analysed. The greater the number 
of stable structures predicted for an aptamer, the greater the chance that some of the RNA in a 
solution will form arbitrary conformations and not a functional aptamer. The structure dot 
plots (Appendix 1) gave a value for the number of base positions that were the same in all 
predicted structures – this is termed the full overlap. P10 had the greatest number of 
overlapping nucleotides at 24, B19 followed with 22. T58 had 17 full overlaps, B11 had 12, 
P2 had 9 and B65 had none. Based on the number of predicted structures, B84 is the most 
likely as there is only one possible conformation. B65 is the least likely as there are three 
predicted stable conformations that share no similarity.  
MFOLD generated a ∆G value for each predicted structures (Figure 7). The ∆G or the 
Gibbs free energy gives an indication of the structure’s stability as it implies the energy 
available for random movement. A negative ∆G indicates a release of energy by the reaction 
indicating it to be more favourable. Thus the structure with the lowest (most negative) ∆G 
was selected as the structure with the best stability and likelihood of existence (Figure 7). 
B11 was the most stable with the lowest ∆G value (-26.80) (Figure 7)whilethe least stable 
structure predicted was for B65 (∆G = -11.30). B84 and P2 had very similar predicted 
stability of ∆G = -19.05 and ∆G = -19.72, respectively. The second most stable conformation 
was for P10 with ∆G = -23.13. The relative order of stability based on the ∆G values was: 
B11, P10, P2, B84, B19, T58 and B65 (Figure 7).  
The degree of structural feasibility was also determined by analysing the pnum values 
for the predicted structures. The pmun value for structure certainty is illustrated with base 
colour (Figure 7). The red and black nucleotides represent those that are most certain and the 
bright colours are an indication of a degree of uncertainty. The chosen structures were those 
with the highest certainty of conformation and those with the lowest ∆G and thus the most 
stable (Figure 7). 
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Name Energy Structure Name Energy Structure 
1. B11 ∆G = -26.80 
  
 5. 
B19 
∆G = -18.78 
 
 
2. P10 ∆G = -23.13 
 
 6. 
T58 
∆G = -18.40 
 
 
3.  
P2 
∆G = -19.72 
 
 7. 
B65 
∆G = -11.30 
 
 
4. 
B84 
∆G = -19.05 
  
 
 
Figure 7: Predicted Secondary Structure of Aptamers by MFOLD.  
Aptamer structures as predicted by MFOLD for the most stable conformation at 37°C. Aptamers
have been placed in order of their relative stability as indicated by the ∆G value.  The pnum
estimation is indicated as colours of the bases.  Red and black indicate regions of conserved
structure while bright colours indicate a level of uncertainty. 
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3.4. Expression and Purification of gp120 
To determine the binding kinetics of the above mentioned aptamers, subtype C gp120 was 
required. Two sets of experiments were run using HIV-1DU151 gp120 and HIV-1CAP45 gp120. 
Only HIV-1DU151 gp120 was expressed for this experiment as HIV-1CAP45 gp120 had been 
previously expressed and was available for use. Glycoprotein gp120 was expressed in 293T 
cells and purified using affinity chromatography1. The purity of the HIV-1DU151 gp120 after 
affinity chromatography was determined by SDS-PAGE (Figure 8) and Western Blotting 
(Figure 9).  
  
SDS-PAGE was used to verify that the protein produced was of the correct size (Figure 8). 
HIV-1ConC gp120 was used as a positive control in both experiments as it is a HIV-1 subtype 
C protein of the same size. HIV-1DU151 gp120 had the same apparent molecular weight as 
HIV-1ConC gp120 as shown in Figure 8.  The Western blot was probed with pooled serum 
from HIV positive individuals (HIV IgG) because it contained antibodies specific to gp120. 
The HIV-1DU151 gp120 band corresponding to the positive control, HIV-1ConC gp120, on the 
Western blot confirmed the presence HIV-1DU151 gp120 (Figure 9). This protein was used for 
gp120 binding kinetics. 
                                                 
 
1 Due to time constraints the purification by affinity chromatography was performed by other individuals from 
the laboratory. 
 
 
 
Figure 9: Western Blot of 
HIV-1DU151 gp120 with Positive 
Control 
Gp120 specific primary antibodies 
identified the gp120 in the western blot. 
HIV-1ConC gp120, was used as the possitive 
control. HIV-1DU151 gp120 and HIV-1ConC 
gp120 were detected  by the 
immunoflourescent assay. 
 
Figure 8: 8% SDS-PAGE Indicating 
Purified HIV-1DU151 gp120 
SDS-PAGE stained with coomassie dye to reveal the 
protein bands. The molecular weight marker was used to 
size the proteins in the respective bands. Positive control 
HIV-1ConC gp120 can be seen at the same height as HIV-
1DU151 gp120. 
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3.5. Validation of gp120 by Binding to IgG b12 
To validate the biological activity of gp120, the protein was tested for binding to b12 
monoclonal antibody (Figure 10). The monoclonal antibody (IgG b12) recognises an epitope 
that overlaps the CD4 binding site and competes with the primary HIV-1 receptor for binding 
(Burton 1994). IgG b12 is a conformation specific antibody that contains cross-clade 
neutralising activity against different HIV-1 subtypes (Trkola 1995). The BIAcore 
sensorgram reached a maximum at which point the graph reached a plateau relative to the 
concentration of the antibody injected. When the injection was stopped, the RU decreased as 
there was no longer analyte passing through the flow cell diffracting the laser (Figure 10). 
The difference between before injection and after injection is the ΔRU and indicates the level 
of binding. In this case, IgG b12 bound with 935 RU (Figure 10). Binding of IgG b12 to 
gp120 indicated that the protein was correctly folded and could be used for subsequent 
experiments. 
 
Figure 10: Monoclonal b12 Antibody Binding HIV-1DU151 gp120.  
The y axis is in response units and the x axis is time in seconds. The start and stop injection point are indicated on the graph. 
An increase in RU is seen after injection and a decrease is seen after the injection has stopped. The plateau after injection 
corresponds to the concentration of injected analyte. The graph was corrected for non-specific binding by removing the 
control flow cell. B12 bound with high affinity and 935 RU. 
 
3.6. Aptamers Isolated against HIV-1BA-L gp120 Bound Monomeric HIV-1DU151 
gp120 
The aptamers raised against HIV-1BA-L were tested for binding to HIV-1DU151 gp120. Binding 
to HIV-1DU151 gp120 had to be confirmed before a kinetic analysis could follow. SPR was 
used to determine aptamer-gp120 kinetics. Of the four flow cells available, three had HIV-
1DU151 gp120 immobilised and the fourth had no protein. The no-protein control was included 
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to correct for non-specific binding to the chip surface. The control graph was included to 
highlight the binding of the aptamer to the protein. Each aptamer was shown to bind with 
differing affinity and those that did not bind were excluded from further analysis (Figure 11). 
 
Figure 11: Aptamers Raised Against HIV-1BA-L Binding to HIV-1DU151 gp120 
The y axis is response units and the x axis time in seconds.  Sensorgrams edited in BIAevaluation indicating the level of 
binding of each aptamer to immobilised HIV-1DU151 gp120. Injection start and stop points are indicated by 1 and 2 
respectively. Binding curves increase after injection (A, C, D, E and F) indicating a change in the refractive index of the 
laser due to the analyte passing the sensor. The drop after injection indicates that the analyte is no longer passing the sensor. 
Sensorgrams drop according to the amount of aptamer bound to the chip surface. The experimental curves are higher than 
the control where the aptamer bound. The control curve returned to base line after injection has finished as no aptamer has 
bound. A: 200 nM UCLA bound with 106 RU B: 150 nM B19 bound with 178 RU. There was a drop in RU after injection 
which was attributed to the buffer effect. C: 200 nM B11 bound with 147 RU. D: 200 nM B84 bound with 85 RU. E: 200 
nM B65 bound with 8 RU. F: 200 nM B5 did not bind DU151 gp120. The experimental curve drops below the starting line 
indicting that immobilised protein may have dislodged during injection. 
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The injection start and stop points are indicated as 1 and 2 respectively (Figure 11). 
The binding experiments were conducted using 200 nM of each aptamer injected for 3 
minutes. For the binding test of B19, 150 nM was used as there was difficulty in transcribing 
this aptamer and so it was conserved for the kinetics experiment for which a large amount of 
RNA was required. The concentration was decided on because it has been previously shown 
to be sufficient for stable binding. There was an increase in the RU at the point of injection 
due to the analyte passing over the sensor surface which caused a change in the refractive 
index of the laser (Figure 11: A, C, D, E and F). This was true for both the control and 
experimental flow cells. In Figure 11: B after injection a drop in response units was seen. The 
drop is caused by the buffer shifting the refraction index in the opposite direction and is 
termed the buffer effect. After the drop, association was seen as B19 was binding to the 
protein. After the injection stopped, the RU increased vertically to the level of binding 
(Figure 11: B).  
The RU level seen on the graph after injection indicated the level of aptamer binding 
to the protein. The difference between control and experimental flow cells was the level of 
binding, expressed as RU (Figure 11).  Aptamers B19, B65, B84, B11 and UCLA were 
shown to bind HIV-1DU151 gp120 with varying RUs (Figure 11: A – E). B5 did not bind and 
the experimental sensorgram ended below that of the control (Figure 11: F). This may 
indicate that the immobilised protein was dislodged during the experiment.  
The control sensorgram is expected to start and end at the same RU level as no 
binding is expected however, this is not always the case due to non-specific associations. As 
B5 did not bind HIV-1DU151 gp120 (-3.6 RU) it was excluded from further analysis. The 
remaining aptamers bound to gp120 with the following RU: 106 RU UCLA, 147 RU B11, 
178 RU B19, 85 RU B84, and 8 RU B65. These aptamers were used for kinetic analysis on 
DU151 gp120. 
 
3.7. Aptamers Isolated against Whole HIV-1CAP45 gp120 Bound HIV-1CAP45 
Monomeric gp120 
P2, P10 and T58 were raised against a whole pseudovirus expressing Env from R5 virus 
called HIV-1CAP45. These aptamers were tested for binding to monomeric gp120 immobilised 
to a CM5 chip using BIAcore SPR (Figure 12). Binding was analysed with 200 nM 
concentrations of each aptamer injected over the protein for 3 minutes.  Although the 
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aptamers were raised against the whole HIV-1CAP45 glycoprotein, it is possible that they 
would not bind the HIV-1CAP45 gp120 monomer.  
The injection start and stop sites are indicated by 1 and 2 respectively (Figure 12). 
After injection there was an increase in the RU for all binding graphs (Figure 12: A, B and 
C). The RUs reached a plateau shortly after injecting P10 (Figure 12: A) indicating a 
saturation of the chip. For P2 and T58 (Figure 12: B and C) no plateau was reached indicating 
that the aptamers had the capacity to bind more. T58 showed the best binding with 739 RU 
followed by P2 with 351 RU and lastly P10 with 90 RU (Figure 12). All three aptamers were 
used in the kinetic analysis on HIV-1CAP45 gp120. 
 
 
 
Figure 12: Aptamer Binding to HIV-1CAP45 gp120 
The y axis is response units and the x axis time in seconds.  Aptamer injection start and stop points are indicated by 1 and 2 
respectively. A: 200 nM P10 binding with 90 RU. A plateau is reached that corresponds to aptamer concentration.  B: 200 
nM P2 binding with 351 RU. No plateau is reached as aptamer has capacity to bind more. C: 200 nM T58 binding with 739 
RU. No plateau is reached as aptamer has capacity to bind more. 
 
3.8. Optimisation of Kinetics Using UCLA on HIV-1DU151 gp120  
The binding kinetics of aptamers shown to bind monomeric gp120 was determined using 
BIAcore SPR technology. The level of protein immobilisation and the flow rate were 
optimised using UCLA against monomeric HIV-1DU151 gp120. UCLA was used as a positive 
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control aptamer as it is known to bind with high efficiency to gp120. If there is high surface 
density of ligand on the chip and the flow rate is too slow, the rate of anylate binding may 
exceed the rate at which it is delivered. This is termed mass transport limitation and can 
negatively affect the kinetic readings and yield a slowed apparent kon than is true. 
To determine the correct level of protein immobilisation needed for kinetic analysis, 
three flow cells with different levels of protein immobilised were used. Initially, the lowest 
possible response units were used (300 RU, 800 RU and 1500 RU immobilised protein). 
However, for the purpose of this study, no data was obtained when the response units were 
set that low as seen in Figure 13. The injection start and stop point are indicated by 1 and 2 
respectively (Figure 13). An increase in RU was seen for each concentration of UCLA after 
injection which decreased back to the base line after injection had stopped, indicating that no 
aptamer was bound to the protein (Figure 13). After the injection of 10 nM UCLA the RU 
spiked higher than that of the other concentrations of UCLA (Figure 13). It was concluded 
that as gp120 is a relatively large molecule it may cause a large change in RU with minimal 
binding and so there was insufficient protein immobilised on the chip for aptamer binding. 
The spike seen with the injection of 10 nM aptamer was regarded as a reading anomaly and 
the experiment was repeated with altered conditions to correct for this. Protein 
immobilisation was increased to 3000 RU, 13 000 RU and 23 000 RU for the second 
optimisation experiment.  
 
 
Figure 13: UCLA Binding Kinetics on Minimum Protein Response Units.  
The y axis represents response units and the x axis is time in seconds. The injection start and stop points are indicated by 1 
and 2 respectively. The coloured lines indicate the different UCLA concentrations injected over the protein. Each aptamer 
concentration is seen to increase after injection and decrease back to base line after injection has stopped. There was no 
change in RU before and after injection indicating no binding to the chip. 
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The chip was activated with EDC:NHS which allowed for the protein to be bound by amine 
coupling. Once activated, the protein was injected onto three flow cells at different 
immobilisation levels. The remaining activated sites on the chip were blocked by 
ethanolamine before Glycine-HCl was injected to remove any partially bound protein. Each 
stage of preparation caused a shift in the refractive index (Figure 14). The resultant RU 
related to the level of immobilised protein. The control flow cell remained at baseline as no 
protein was injected. 
 
 
Figure 14: Preparation of CM5 Chip for Kinetic Analysis of UCLA on HIV-1DU151 
gp120.  
The y axis is response units and the x axis time in seconds.  EDC:NHS activated the chip prior to protein binding. A different 
amount of protein was injected into three flow cells with a fourth with no protein. Ethanolamine blocked any remaining 
active sites and Glycine-HCl knocked off weakly bound protein. The resultant RU indicates the amount of protein 
immobilised on each flow cell. The flow cells had 23 000 RU, 13 00 RU and 3 000 RU immobilised. 
 
The different aptamer concentrations were injected in ascending order over all four 
flow cells. The standard deviation for each experimental condition could not be calculated as 
no repetitions were included. The dissociation constant (Kd) was obtained for each flow cell 
independently. The Kd was calculated (by BIAevaluation software) using the k(on), k(off) 
values and aptamer concentrations. The k(off) represents the global dissociation value 
calculated for the dissociation of the aptamer in each flow cell. This value was calculated 
independent of aptamer concentration and association. The k(on) value takes into account the 
k(off) and the aptamer concentrations used and was a global association value. The Chi2 
value associated with each calculation gave an indication of goodness of fit with a value of 1. 
The k(on) and k(off) were calculated separately using the 1:1 Langmuir Binding Model and a 
Chi2 value was calculated for each step. The same method of kinetic analysis was applied 
when analysing the results of all kinetics experiments.  
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The result for flow cells immobilised with 23 000 RU and 13 000 RU was very 
similar and the associated Chi2 values indicated confidence in the result (Table 4). The 
aptamers separated in a concentration dependent manner with the highest injected 
concentrations having the highest RU (Figure 15).  
 
Table 4: Calculated Constants and Associated Chi2 Values for UCLA Kinetics on HIV-
1DU151 gp120 
K(off) – calculated value for ligand dissociation, not dependent on Concentration and k(on) 
K(on) – calculated value for ligand association based on Concentration and k(off) 
Kd – dissociation constant for the reaction calculated using the Concentration, k(on) and k(off) 
 
Protein RU Flow Cell k(off) Chi2 k(on) Chi2 Kd 
23 000 1 0.015 1.9 4.42e5 0.2 3.39e-8 
13 000 2 0.015 0.347 4.26e5 0.04 3.52e-8 
3000 3 0.015 0.289 6.53e5 4.22e3 2.3e-8 
 
The association appeared rapid with a steep incline while the dissociation was slower 
with a duller gradient. After 150 seconds the dissociation became gradual and the aptamer 
remained stably bound to the protein for both flow cell immobilisations (Figure 15). The Kd 
calculated for the flow cell with 23 000 RU gp120 was 33.9 nM (Figure 15: A) and for 
13 000 RU gp120 was 35.2 nM (Figure 15: B).   
 
 
Figure 15: UCLA Binding Kinetics on HIV-1DU151 gp120.  
The y axis indicated the response units caused by binding to the protein. The x axis shows time in seconds. The coloured 
lines indicate the different aptamer Concentrations injected over the immobilised protein. The association and dissociation 
periods have been highlighted on each graph. A: UCLA kinetics on 23 000 RU HIV-1DU151 gp120. The resultant Kd was 
calculated as 33.9 nM. B: UCLA kinetics on 13 000 RU DU151 gp120. The resultant Kd was calculated as 35.2 nM. 
 
When kinetics data was obtained from the flow cell with 3000 RU gp120, the Kd 
decreased to 23 nM (Figure 16). More notably, the graph for 3000 RU immobilised inverted 
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where higher concentration aptamers appeared to bind less than the lower concentration 
aptamers resulting in lower RU after dissociation (Figure 16). The dissociation appeared 
much more rapid than on the flow cells with more protein immobilised (Figure 16). The Chi2 
value for the calculated k(on) was 3 orders of magnitude larger than that of the other two 
experimental flow cells indicating reduced confidence in the accuracy of the result (Table 4). 
It was concluded that 3000 RU of immobilised protein was below the minimum requirement 
for adequate binding and thus for further kinetics studies 13 000 RU – 23 000 RU 
immobilised gp120 was used.  
 
 
Figure 16: UCLA Binding Kinetics on 3000 RU HIV-1DU151 gp120 
The y axis is in response units and the x axis is time in seconds. The dissociation gradient was very steep indicated in red on 
the graph. The coloured lines indicate the different UCLA concentrations injected over the protein. The curves separated 
according to concentration but the lowest concentration aptamer resulted in the highest RU. The resultant Kd was calculated 
as 23 nM. 
 
3.9. Further Optimisation of Kinetics on HIV-1DU151 gp120 
The parameters determined for UCLA on HIV-1DU151 gp120 provided the foundation for 
further optimisation. The concentration of aptamer injected over the immobilised protein was 
optimised using B84, B65 and B19 on HIV-1DU151 gp120. Optimisation was conducted in 
triplicate so a statistical analysis could be applied to the results and the standard deviation 
calculated. The chip was activated with EDC:NHS prior to binding protein to three flow cells, 
a fourth contained no protein  (Figure 17). The same amount of protein was immobilised to 
three flow cells. The remaining active sites were blocked with ethanolamine and the weakly 
bound protein was removed with a Glycine-HCl wash (Figure 17).  
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Figure 17: Preparation of CM5 Chip for Kinetics Experiments 
The y axis is response units and the x axis time in seconds. The chip was activated with EDC:NHS before protein was 
injected into three flow cells. The same amount of protein was injected into three flow cells and a fourth had no protein. 
Ethanolamine blocked remaining active sites and Glycine-HCl removed weakly bound protein. The protein RU for the three 
flow cells differed slightly. 
 
Initial experiments used B65, B19 and B84 and identified that 13 000 RU 
immobilised protein was insufficient for kinetic analysis (outlined in Appendix 2). They also 
showed that although 500 nM UCLA bound with high affinity to the immobilised protein, 
this was too high for the aptamers used in this study (Appendix 2). These kinetic experiments 
generated very low Kd values with very high associated Chi2 values. The associated kinetics 
graphs showed a discrepancy in the expected profile when the aptamer concentrations used 
for the UCLA optimisation experiment were used (Appendix 2).  
Further optimisation of aptamer concentration used only B84 as it transcribed with the 
highest efficiency. Briefly, three concurrent flow cells were loaded with 13 000 RU HIV-
1DU151 gp120. The aptamer kinetics was determined to fit the 1:1 Langmuir binding model; 
however the associated graph illustrated the incorrect binding profile (Appendix 2). While the 
more concentrated aptamer solutions are expected to end with the highest RU, the graph 
demonstrated a different but not fully inverted profile (Appendix 2: Figure iii). The 200 nM 
and 500 nM solutions grouped together below 70 nM and above 30 nM. It was concluded that 
these concentrations were too high for aptamer binding due to increased competition for 
binding. An excess of aptamer injected over the protein surface may result in unbound 
aptamer knocking off the bound aptamer as it passes the chip surface. To test this,  a 
reduction in aptamer concentration was explored to correct this.  
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A 70 nM concentration was chosen as the upper limit decreasing with half log 
dilutions to 0.5 nM (Appendix 2: Figure iv). Below 14 nM the aptamer was unable to cause a 
significant change in the refractive index and a result was not given which lead to the 
inversion of the expected binding profile (Appendix 2: Figure iv). A further kinetic 
experiment was set up with the upper concentration limit of 70 nM and the lower 
concentration limit of 14 nM (Appendix 2: Figure v). This proved to be too narrow a window 
for meaningful results as selected concentrations were too similar to produce a valid Kd 
(calculated as 2.84 × 103 nM ± 2.1 × 103). It was thus decided to raise the upper concentration 
limit to 150 nM chosen based on previous experiments showing partial success of 100 nM 
and 200 nM. To generate a minimum of five data points a 2 fold dilution was used resulting 
in concentrations of 150 nM, 75 nM, 37 nM, 18.5 nM, 9 nM, 4.5 nM. This experiment proved 
successful (results outlined in 3.10.1.) and the parameters were then used in all subsequent 
kinetics experiments. 
 
3.10. Aptamer Binding Kinetics on HIV-1DU151 gp120 
B11, B65 and B84 binding kineticswere determined on HIV-1DU151 gp120. Insufficient B19 
was generated for kinetic analysis and so was excluded even though it bound monomeric 
HIV-1DU151 gp120. The parameters determined in the optimisation experiments outlined in 
3.8 and 3.9 were used for kinetic experiments on both HIV-1CAP45 gp120 and HIV-1DU151 
gp120. BIAevaluation software was used to analyse the results and the empty flow cell was 
deducted from the experimental results to correct for non-specific binding and instrument 
noise. The separate ka / kd kinetic analysis tool was used to calculate the Kd and associated 
Chi2 values. The 1:1 Langmuir Binding model was used for the calculation of the Kd. This 
model states that for each ligand there can only be one analyte bound. The results were 
expressed as sensorgrams indicating the association and dissociation period of the aptamer 
concentrations to the protein. 
 
3.10.1. B84 Kinetics on HIV-1DU151 gp120 
B84 bound to monomeric HIV-1DU151 gp120 with the second lowest RU of 85 RU. The 
association of B84 followed a concentration dependent gradient for most injected 
concentrations (Figure 18). The final binding RU for the aptamer concentrations distributed 
according to concentration except for 150 nM and 9 nM (Figure 18). At 150 nM the 
dissociation ended below the lower aptamer concentrations. This concentration may be too 
high for B84 binding. The 9 nM injection did not follow the same gradient as the other 
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concentrations (Figure 18). The association of 9 nM peaked higher than expected and the 
binding appeared stronger than expected (Figure 18). This result may have been due to some 
of the anylate from the previous flow through remaining bound to the chip surface 
compounding the binding response. This was not seen with the following injection (Figure 
18, 18.5 nM) indicating that the bound aptamer was fully removed prior to subsequent 
injections. The other aptamer concentrations follow a concentration dependent binding 
pattern (Figure 18). . The dissociation of each of the concentrations was steady and the 
aptamer remained bound after 50 seconds (Figure 18) indicating a stable interaction. The Kd 
for B84 binding was calculated to be 23 nM ± 8 with the associated Chi2 values within the 
range of statistical significance (Table 5).  
 
Figure 18: B84 Binding Kinetics on HIV-1DU151 gp120 with Increased Concentration 
Limits.  
The y axis is response units and the x axis time in seconds. Association and dissociation regions are indicated. Each coloured 
line represents a different concentration of B84 injected. All aptamer concentrations dissociate slowly after injection has 
stopped. The different aptamer concentrations are clearly distinguished from one another. The higher concentration aptamers 
result in higher RU.    
 
Table 5: Calculated Constants and Associated Chi2 Values for B84 Kinetics on HIV-
1DU151 gp120.  
  
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 0.0209 0.296 1.06e-6 0.947 1.97e-8 
2 0.0248 0.124 1.43e-6 0.244 1.73e-8 
3 0.0211 0.744 5.91e-6 1.34 3.57e-8 
AVERAGE 0.0222 0.388 2.8e-6 0.843 2.3e-8 
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3.10.2. B65 Kinetics on HIV-1DU151 gp120 
B65 showed very low binding to HIV-1DU151 gp120 of 8 RU but was included for kinetic 
analysis to determine the effect of low RU on kinetic analysis.  Although from the statistical 
analysis the resultant Kd was statistically significant (Table 6), the curve provided little 
confidence in the result (Figure 19). The association of each aptamer concentration was 
erratic and the curve showed many peaks and deviations (Figure 19). The RU change was not 
a reflection of the concentration injected and 4 nM resulted in a higher association RU than 
all greater concentrations with the exception of 300 nM (Figure 19). The dissociation phase 
again did not represent the concentration dependent RU result as the high and low 
concentrations grouped together in an erratic manner (Figure 19). This may indicate that a 
low RU binder is not a good candidate for kinetic analysis even if a statistically relevant 
result can be obtained. The statistical values associated to the calculated k(on) and k(off), 
used for the Kd calculation were not supported by the sensorgram (Table 6). 
 
 
Figure 19: B65 Binding Kinetics on HIV-1DU151 gp120.  
The y axis is response units and the x axis is time in seconds.  The coloured lines indicate the different P10 concentrations 
injected over the protein. The RU change was not a reflection of the concentration injected. The association and dissociation 
periods are indicated. The association period is erratic and each aptamer concentration had a different gradient. The 
dissociation is not according to injected concentration. All aptamer concentrations end above the baseline. There is a steep 
gradient during the dissociation phase. 
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Table 6: Calculated Constants and Associated Chi2 Values for B65 Kinetics on HIV-
1DU151 gp120. 
  
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 9.61e-3 1.36 1.77e5 0 5.43e-8 
2 8.41e-3 0.983 2.07e5 0 4.06e-8 
3 8.43e-3 1.23 1.43e5 0 5.88e-8 
AVERAGE 8.82e-3 1.19 1.76e5 0 5.12e-8 
 
3.10.3. B11 Kinetics on HIV-1DU151 gp120 
B11 was shown to bind to HIV-1DU151 gp120 with 147 RU and was the second highest value 
for binding to HIV-1DU151 gp120. The kinetic analysis of B11 revealed it as a weaker binder 
than the other aptamers tested on HIV-1DU151 gp120 (Kd = 179 nM ± 81) (Figure 20).   
 
 
Figure 20: B11 Binding Kinetics on HIV-1DU151 gp120.   
The y axis is response units and the x axis time in seconds.  The association and dissociation periods are indicated. Each 
coloured graph indicates a different B11 concentration injected. All concentrations had a steep dissociation and a mild 
association gradient. Higher concentration aptamers grouped at the same RU while differentiation was seen between the 
lower concentrations. The Kd was calculated as 179 nM ± 81. 
 
The association and dissociation periods are indicated on the graph (Figure 20). The 
dissociation of all aptamer concentrations was rapid with the lowest concentration (4.5 nM) 
falling down to the base line (Figure 20). This rapid dissociation, indicative of weak 
interaction strength was confirmed by the calculated Kd. The higher concentration aptamers 
(75 nM, 200 nM and 300 nM) group together during both the association and dissociation 
phases (Figure 20).  
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Table 7: Calculated Constants and Associated Chi2 Values for B11 Kinetics on HIV-
1DU151 gp120. 
 
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 0.0376 0.988 1.89e5 0 1.99e-7 
2 0.0345 1.41 1.33e5 0 2.59e-7 
3 0.0392 1.25 6.95e5 0 7.95e-8 
AVERAGE 0.0371 1.216 3.39e5 0 1.79e-7 
 
The association of each concentration was very gradual which may indicate a low affinity for 
the protein indicated by the calculated k(on) value (average 3.39e5) (Table 7). Of all 
aptamers tested on HIV-1DU151 gp120, B11 showed the highest Kd even though the binding 
RU was among the highest. 
 
3.11. Aptamer Kinetics on HIV-1CAP45 gp120 
The aptamers raised against HIV-1CAP45 pseudovirus (P10, T58, P2) were tested for binding 
to monomeric HIV-1CAP45 gp120. All three aptamers were found to bind with varying RU (90 
RU to 739 RU). The parameters identified in the optimisation experiments on HIV-1DU151 
gp120 were used for the kinetic analysis on HIV-1CAP45 gp120. For each aptamer, 
concentrations ranging from 5 nM to 300 nM were injected over four flow cells on a research 
grade CM5 chip. Three flow cells loaded with 20 000 RU immobilised protein and the fourth 
flow cell contained no protein. The no protein control was used to correct for non-specific 
binding to the chip and instrumental noise. The results were expressed as sensorgrams 
indicating the association and dissociation period of the aptamer concentrations to the 
protein. All aptamers were analysed using the separate ka/ kd analysis tool using the 1:1 
Langmuir Binding Model.  
 
 3.11.1. P10 Kinetics on HIV-1CAP45 gp120 
P10, the weakest binder of the three HIV-1CAP45 aptamers revealed the highest Kd of 221 nM 
± 81. The aptamer started to dissociate before the full association time had passed (Figure 
21). This is a clear indication of its loose binding to the protein. The higher concentrations 
(100 nM and 200 nM) did not form distinct lines and ended at the same RU after dissociation 
(Figure 21). The lower concentrations (5 nM to 50 nM) also ended at the same point but 
much closer to the base line (Figure 21). The lower concentration aptamers appeared to have 
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almost fully dissociated from the protein 50 seconds after injection stopped while the higher 
concentration  aptamers remained bound with 50 RU (Figure 21). The associated statistical 
analysis indicated confidence in the result (Table 8). The Chi2 associated with the k(on) for 
all flow cells was 0 and for k(off) was close to 1.  
 
 
Figure 21: P10 Binding Kinetics on HIV-1CAP45 gp120.  
The y axis is response units and the x axis time in seconds.  The association and dissociation periods are indicated on the 
graph. The coloured lines indicate the different P10 concentrations injected over the protein. Dissociation of all aptamer 
concentrations appears to start before injection is finished. The lower concentration aptamers appear to have almost fully 
dissociated 50 seconds after injection is stopped. The higher concentration aptamers remain bound although with low RU. 
The resultant Kd was 221 nM ± 81.  
 
Table 8: Calculated Constants and Associated Chi2 Values for P10 Kinetics on HIV-
1CAP45 gp120. 
 
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 0.0394 1.88 1.86e5 0 2.12e-7 
2 0.0438 0.892 1.39e5 0 3.16e-7 
3 0.0397 1.78 2.95e5 0 1.35e-7 
AVERAGE 0.041 1.52 2.07e5 0 2.21e-7 
 
3.11.2. T58 Kinetics on HIV-1CAP45 gp120 
T58 bound with the highest RU of all aptamers tested against HIV-1CAP45 gp120 with 739 
RU. Kinetics curves indicated that T58 did not dissociate rapidly from HIV-1CAP45 gp120 
(Figure 22). The dissociation phase had a very slight gradient indicating a slow dissociation 
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from the protein. The aptamers separated in a concentration dependent manner with clear 
distinction between the upper concentrations however, the lower concentrations (18 nM and 
37.5 nM) cannot easily be individually distinguished (Figure 22). 
 
 
Figure 22: T58 Binding Kinetics on HIV-1CAP45 gp120.   
The y axis is response units and the x axis time in seconds.  The coloured lines indicated the different aptamer concentrations 
injected over the protein. The association and dissociation phases are indicated. A steep gradient is seen for the association 
period. All aptamer concentrations remained bound to the protein after the dissociation period.   
 
The calculated Kd (33 nM ± 14), although relatively low, was expected to be lower as the 
aptamer remained stably bound after dissociation (Figure 22). The Chi2 values associated 
with the k(on) and k(off) values used in the calculation of the Kd indicated confidence in the 
result (Table 9).  The Kd calculated for T58 was similar to that of truncated B40, Kd = 31.2 
nM, (Dey 2005), which is known as a strong binder of gp120.   
 
Table 9: Calculated Constants and Associated Chi2 Values for T58 Kinetics on HIV-
1CAP45 gp120. 
  
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 3.31e-3 1.92 8.4e4 0 3.92e-8 
2 2.91e-3 1.7 5.24e4 0 5.52e-8 
3 3.09e-3 2.26 1.42e5 0 2.17e-8 
AVERAGE 3.10e-3 1.96 9.28e4 0 3.3e-8 
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3.11.3. P2 Kinetics on HIV-1CAP45 gp120 
P2 bound with 351 RU to monomeric HIV-1CAP45 gp120 placing it second of the three 
aptamers in terms of binding, after T58 and before P10. The kinetic analysis revealed P2 as 
the strongest binder with the tightest association (Figure 23; Table 10). The association phase 
had a very steep gradient in a concentration dependent manner (Figure 23).  
 
 
Figure 23: P2 Binding Kinetics on HIV-1CAP45 gp120.   
The y axis is response units and the x axis time in seconds.  Each coloured line indicates a different concentration of P2 
injected. The association and dissociation phases are indicated. The upper concentration aptamers remain bound after the 
dissociation phase. The lower concentration aptamers dropped close to the base line. The resultant Kd was 16.9 nM ± 5.5. 
 
After injection had stopped, the higher concentration aptamers (300 nM, 150 nM and 75 nM) 
remained stably bound to the protein after 100 seconds of dissociation while the lower 
concentration aptamers (5 nM to 37.5 nM) dropped almost to the base line (Figure 23). 
Although P2 did not bind HIV-1CAP45 gp120 with the highest RU, it had the strongest and 
most stable interaction. 
 
Table 10: Calculated Constants and Associated Chi2 Values for P2 Kinetics on HIV-
1CAP45 gp120. 
  
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 6.47e-3 1.27 2.68e5 0 2.41e-8 
2 5.68e-3 0.77 4.02e5 0 1.41e-8 
3 4.61e-3 0.56 3.67e5 0 1.26e-8 
AVERAGE 5.59e-3 0.86 3.46e5 0 1.69e-8 
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4. Discussion 
 
As the aptamers were selected from such diverse libraries they were expected to form diverse 
structures. The predicted secondary structures differed in number predicted and 
conformation. Aptamer B84 had only one predicted structure which implied an increased 
level of certainty in the likelihood of that structure. The most structures were predicted for P2 
(5 structures) which implied that the RNA may form arbitrary conformations other than that 
required for the aptamer. In turn, this may mean that the aptamer could be competed out by 
other, non binding structures. The difference between conformations was important for 
consideration as it indicated the diversity of the aptamer structures possible. P10 had the most 
overlapping bases (24 bases) between all four predicted conformations. P2 had the least 
overlaps (9 bases) which indicated diversity in possible conformations. The structure with the 
lowest ΔG was most likely of the predicted aptamer conformation. The lower the ΔG, the 
more inherently stable a conformation and the more likely it will form the basis of the tertiary 
structure required for aptamer binding. The most stable conformation as predicted by 
MFOLD was for B11 as it had the lowest ΔG value and three predicted conformations with 
significant overlaps. B65 was predicted with the least stable conformation with the largest ∆G 
of -11.30 and three predicted stable conformations that share no similarity.  
  As much as secondary structure provides an insight into the number of possible 
conformations and the predicted stabilities, it is the RNA in tertiary structure that interacts 
with the protein. To gain better insight into the RNA conformations an analysis of tertiary 
structure and the possible protein aptamer interaction could be addressed. This may have 
included, amongst others: RNAse digestion, circular dichroism, RNA footprinting and x-ray 
crystallography. RNAse digestion (Vary 1984) and circular dicroism (Hashizume 1967) can 
be used as methods to validate the predicted secondary structures.  X-ray crystallography 
(Kim 1968) would provide tertiary structure information while RNA footprinting (Galas 
1978) would provide information regarding the sequence motifs involved in protein binding. 
Binding kinetic analysis reveals the relative strength of the aptamer-protein 
interaction. This has significant implications for the design of aptamer based therapeutics. A 
strong aptamer-protein interaction would have implications for both inhibitor and targeting 
aspects of aptamer based therapy. As an entry inhibitor, the stronger the aptamer binding is to 
gp120, the stronger the inhibition. This has been shown for antibody binding and 
neutralisation of SIV entry (Steckbeck 2005). Similarly, a strong aptamer-protein interaction 
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would increase contact time for the delivery of a therapeutic. The investigation of the binding 
kinetic properties of the aptamers identified them as highly diverse.  A previous study by Dey 
et al (2005) reported a Kd of 31.3 ± 2 nM for B40t77 (truncated B40). This is similar to that 
of UCLA calculated between 33.9 nM and 35.2 nM. The similarity was expected as UCLA is 
a commercially available version of B40t77 modified for enhanced structural stability. The 
BIAcore user manual suggests using the lowest possible response units of immobilised 
protein. Previous studies  (Khati 2003; Dey 2005) used 1000 RU, 5000 RU and 10 000 RU 
gp120 immobilised to the three experimental flow cells and none to a binding control flow 
cell. When these conditions were used, no aptamer binding was noted. This could be 
explained by the size of the gp120 protein. The bigger a binding molecule is, the higher the 
response units are with each individual molecule added. Thus the final response units have to 
be quite large for a larger molecule. By having a low response unit for gp120 binding there 
was not enough protein present on the chip for binding of the selected aptamers to occur. 
When the UCLA optimised experimental conditions were repeated for (less 
characterised) aptamers B65, B19 and B84 the Kd could not be elucidated. The 1:1 Langmuir 
binding model showed an inverse in the graphs and no reading could be taken from them. 
This may indicate a saturation of the chip with the response units selected. At lower aptamer 
concentrations, the curves followed the expected gradient. When the concentration was 
increased, however, the graphs plummeted and ended below that of the lower concentration 
aptamers. This may indicate that the saturation point is reached early and the higher 
concentration was acting as to inhibit binding. When the concentration was increased the 
aptamers may have inhibited one another by competition and / or steric hindrance.   
Using a further optimised protocol, the Kd of each aptamer was calculated. The Kd 
calculated for each aptamer can be seen in Table 11 below in order from smallest to largest 
with their associated ∆G as predicted by MFOLD. B40t77 was included as a standard for 
good gp120 binding kinetics. For the sake of comparison a standard deviation for UCLA was 
created from the results on 23 000 RU and 13 000 RU HIV-1DU151 gp120. Two aptamers (P2 
and B84) showed a Kd smaller than that of B40t77 (Table 11). The majority of the aptamers 
were grouped within the same range of B40t77 with only P10 and B11 giving a much higher 
Kd (Table 11). B65 showed a Kd similar to that of B40t77 and although the statistical analysis 
provided Chi2 values within the accepted range,  the curve provided little confidence in the 
result. B65 was predicted with three completely different structures. This could indicate that 
the transcribed RNA did not fold into the aptamer conformation with great efficiency 
resulting in arbitrary conformations that confounded the result. Because of this B65 was not 
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considered a good candidate for further study. P2 and B84 were identified as the best 
candidates for further study as they have been shown to bind stably over time and have stable 
secondary structures when compared to the other aptamers. 
 
Table 11: Comparison of Aptamer Kd and Most Probable Structure ∆G 
 
Aptamer Kd ∆G 
P2 16.9 nM ± 5.5 -19.72 
B84 23 nM ± 8 -19.05 
B40t77* 31.2 nM ± 2 -23.79 
T58 33 nM ± 14 -18.4 
UCLA# 34.5 nM ± 0.7  
B65 51 nM ± 8.5 -11.3 
B11 179 nM ± 81 -26.8 
P10 221 nM ± 81 -23.13 
*B40t77 highlighted in red was included as a standard for aptamer dissociation, ∆G from MFOLD 
#UCLA highlighted in orange has a standard deviation calculated from the 23 000 RU and 13 000 RU results, no ∆G was 
provided as MFOLD predictions do not account for additional modifications  
 
The standard deviation for the calculated aptamers Kd is systematically higher than that for 
B40t77. This could be improved with more replicates as only three replicates were included 
in this study. Although the standard deviations are higher, they remain less than one third of 
the total indicating a tight grouping of results. The higher standard deviation can also be 
attributed to the use of only the BIAcore when calculating the Kd. The use of the BIAcore can 
induce variability in results if there are differences with the flow of the different flow cells on 
the chip. As the BIAcore is controlled by a nearby computer, there is little user interaction 
and thus one is reliant on its accuracy. By including more than one kinetic analysis method, 
the inherent variations could be reduced although experimental variation would persist. 
Numerous methods exist for the determination of binding kinetics, one of which is Quartz 
crystal microbalance with dissipation (QCM-D). QCM-D monitors a change in frequency as 
a result of added mass (Dixon 2008). This method can be used to detect a variety of 
interaction including: protein-protein, antibody-antigen and DNA-DNA (Dixon 2008). The 
drawback to this method is that it is only valid for rigid molecules as molecule movement 
could interrupt the detection of oscillations and that it requires molecules to be labelled for 
their immobilisation. This made the use of this technique for the purpose of this study 
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inappropriate. By labelling the molecules used, information can no longer be gained on native 
molecules and their interaction which could lead to misleading results and inaccurate 
conclusions. A great advantage to the use of SPR is the sensitivity to changes in mass and as 
such molecules do not need to be labelled for their interaction to be identified. Other 
advantages include that SPR can be used with relatively small amounts of materials and it 
provides a real time analysis of association and dissociation rates (Johnsson 1991; Crouch 
1999). Initially there was intention of measuring the Kd using an Electro Mobility Shift Assay 
(EMSA) to corroborate the BIAcore results.  
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5. Further studies 
 
With the time constraints on this project, all aspects of the aptamer protein interaction could 
not be explored. Outlined below are experiments that could be used to enhance the 
information gained from this project.  
RNA footprinting and competition assays for the aptamers would be essential to 
elucidate the binding position on both the aptamer and the protein. RNA footprinting involves 
the degradation of the RNA while bound to the protein. The region bound to the protein is 
protected from degradation and can be detected by resolving on a non-denaturing gel (Galas 
1978). By identifying the minimal sequence required for binding, aptamers can be truncated 
to include only the essential sequence. Smaller molecules are less affected by steric hindrance 
and can more easily navigate through the human body as a therapeutic. Aptamers of reduced 
size would be less expensive to produce which is an important consideration for large scale in 
vitro production. A competition assay would identify if the aptamer bound a known 
neutralising epitope or if it bind a novel site (Henry 1985). This would indicate its ability to 
be used in conjunction with other gp120 binding therapeutics. 
Circular dichroism can be used to corroborate the secondary structures predicted by 
MFOLD. The signal detected differs if RNA molecules are folded in different orientations. 
This can be used to elucidate secondary structure information (Hashizume 1967).  
More than one kinetics analysis could be conducted to further strengthen the results 
obtained on the BIAcore. An EMSA could be conducted to provide this information. RNA-
protein complexes are resolved on a polyacrylamide gel. A shift in band height between 
bound and non-bound RNA fractions corresponds to the concentration of the bound complex 
relative to the total RNA and protein concentration is solution. This shift can be quantified 
and used for the analysis of binding kinetics (Garner 1981).  
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6. Conclusion 
 
Structural stability and likelihood was based on the number of predicted structures, between 
structure similarity and associated structural ∆G values. B11 and B84 were identified as the 
most stable and B65 as the least stable aptamer.  In the kinetic analysis, B11 and P10 were 
seen to have the highest dissociation constants of 179 nM ± 81 and 221 nM ±81 respectively. 
This indicates that they are possibly not good candidates for further analysis. The other 
aptamers had dissociation constants similar to or lower than B40t77 and so could be good 
candidates for further characterisation with exception of B65. Kinetic analysis of B65 
indicated a similar dissociation constant to B40t77, a strong gp120 binding aptamer. 
Although the statistical analysis provided Chi2 values within the accepted range, the curve 
provided little confidence in the result. The MFOLD predictions identified three possible 
structures with no structural similarity for B65. This may have resulted in the RNA in 
solution not forming the conformation required for binding. As such, B65 was identified as a 
poor candidate for further characterisation. The best binder with the lowest calculated 
dissociation constant was P2 with Kd = 16.9 nM ± 5.5. However, P2 was tested against 
monomeric gp120 from CAP45, the same viral strain to which it was raised. Further study of 
binding kinetics on proteins from other variants would provide further insight into its possible 
use. Five secondary structures were predicted for P2 with a portion of similarity between all 
of them. B84 was identified as the second best aptamer candidate with only one predicted 
structure and strong protein interaction (Kd =23 nM ± 8). The binding kinetics provides 
insight into the protein aptamer interaction strength. The lower the Kd of an aptamer, the 
stronger the interaction and more stable the binding. Aptamers with a low Kd could have 
improved bioavailability as they are able to bind their target for longer and avoid clearance 
from the body. This study has highlighted B84 and P2 as aptamers as possible therapeutic 
molecules for which further characterisation should follow. 
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Appendix 1 
 
Structure Dot Plots for the aptamers with more than one predicted conformation. Structure dot plots indicate the aptamer name and the 
number of predicted structures. This in addition to the pnum and ∆G was used to determine the most stable and likely conformation.  
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Appendix 2 
 
Optimisation Experiments for Kinetics 
B65 kinetic was determined on the UCLA optimised 13 000 RU HIV-1DU151 gp120.  Three 
concurrent kinetics experiments were run on three flow cells loaded with 13 000 RU HIV-
1DU151 gp120 with the fourth left empty as a no protein control. B65 binding appeared to fit 
the 1:1 Langmuir model however, on closer inspection it was noted that the graph had not 
followed the expected concentration gradient (Figure i). After injection the aptamer 
concentrations did not deviate in a concentration manner (Figure i). The second highest 
concentration (200 nM) resulted in maximum RU lower than the less concentrated aptamers 
(Figure i). At the start of dissociation there was a difference in aptamers of different 
concentrations. After 40 seconds the aptamer concentrations no longer deviated and 500 nM 
had the lowest RU (Figure i).   
 
 
Figure i: B65 Binding Kinetics on 13 000 RU HIV-1DU151 gp120.  
The aptamer concentrations did not diverge from one another in the expected pattern. The concentrations were too close for 
adequate analysis. As such, the calculated Kd of 2.7e3 cannot be taken as an accurate result even though the Chi2 analysis 
showed the results to be significant. 
 
The average dissociation constant was calculated and the standard deviation was determined 
(Table i). There was a large variation in calculated Kd for each flow cell. Using the separate 
ka / kd calculation, B65 was shown to have a Kd = 2.7e3 nM ± 2.2e3.  The Chi2 calculated for 
the experiment fit within a reasonable range which indicated statistical significance. The 
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values were similar between two flow cells with one as an outlier for all three calculations. 
The large standard deviation was testament to the high variability between flow cells. When 
analysed with the simultaneous ka / kd, the Chi2 value was more than two orders of 
magnitude higher and the Kd more than two orders of magnitude lower. Due to the lack of 
deviation between concentrations it was concluded that the concentrations were too similar 
for a reliable calculation to be generated. As 500 nM proved to be too concentrated for 
aptamer binding, the upper limit concentration would start at 200 nM and reduce in half log 
dilutions.  
 
Table i: Calculated Constants and Associated Chi2 values for B65 Kinetics on HIV-
1DU151 gp120 
 
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 0.0226 0.0167 2.4e4 0.01 9.4e-7 
2 0.0309 0.0197 1.72e4 0.01 1.79e-6 
3 0.0329 0.006 5.82e-3 0.007 5.66e-6 
Average     2.7e-6 
 
The experiment was repeated for B19 (excluding 500 nM) to test if another aptamer would 
follow the same trend. B19 fit the 1:1 Langmuir Binding model to the same extent as B65. 
The kinetics graph followed the same general trend with the different concentrations 
clumping together (Figure ii). The more concentrated aptamer samples grouped at almost the 
same response unit level while 30 nM ended much lower down (Figure ii).  
 
 
Figure ii: B19 Binding Kinetics on HIV-1DU151 gp120.  
The coloured lines indicate the aptamer concentrations injected. The upper concentrations for B19 clumped together while 
30 nM was very distinct. The calculated Kd = 100 nM ± 61.8.  
 
Page | 56  
 
The Kd was calculated and the standard deviation determined with the associated Chi2 values 
(Table ii). The Kd was calculated as 100.6 nM ± 61.8. Again a very high standard deviation 
was seen, this was attributed to injected aptamer concentrations being indistinguishable 
which lead to an inaccuracy in the calculations. When calculating the k(on), the concentration 
is an important factor and since there was no concentration variation, this may have 
introduced an error into the calculation. 
 
Table ii: Calculated Constants and Associated Chi2 values for B19 Kinetics on HIV-
1DU151  gp120 
 
Flow Cell k(off) Chi2 k(on) Chi2 Kd 
1 2.9e-3 0.070 1.40e5 0 2.08e-8 
2 6.35e-3 0.101 4.54e4 0 1.4e-7 
3 0.0128 0.995 9.08e4 0 1.41e-7 
Average 7.35e3 0.398 9.21e4 0 1.0e-7 
 
Associated Graphs for B84 Optimisation on DU151 
 
  
Figure iii: B84 Binding Kinetics on HIV-1DU151 gp120.  
B84 fits 1:1 Langmuir binding model and the binding curve does not the expected line. Higher concentrations group together with 
200 nM and 500 nM below 70 nM and 100 nM. 30 nM ends with the lowest response units as expected. The dissociation constant 
was calculated by taking the average of three concurrent experiments and the standard deviation was determined. B84 is shown to be 
a tight binder with Kd = 6.5 nM ± 2.8. 
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Figure iv: B84 Kinetics on HIV-1DU151 gp120 with reduced aptamer concentration.  
To overcome the problems with saturation found with previous experiments, a reduced aptamer concentration was used. Half log 
dilutions from 70 nM to 0.5 nM were prepared and run on a chip loaded with 10 000 RU. Aptamer concentrations below 14 nM 
appeared to be below the limit of detection and thus the curve did not follow the expected gradient for all concentrations.  
Figure v: B84 kinetics on HIV-1DU151 gp120 with reduced concentration limits.  
The previously determined concentration limits were established and concentrations between were chosen. Six data points were used 
in the determination of the dissociation constant. These points appear to be too similar to provide meaningful results. The upper limit 
for kinetics must be raised to allow for a larger difference between sample concentrations. 
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